QUARTERLY REPORT

Q3 2023 — Form 10-Q

Q3 2023PDF · 49 pages530 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________________________
FORM 10-Q
________________________________________________________
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
For the quarterly period ended September 29, 2023
OR
☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 001-08089
DANAHER CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 59-1995548
(State of Incorporation) (I.R.S. Employer Identification Number)
2200 Pennsylvania Avenue, N.W., Suite 800W 20037-1701
Washington, DC
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: 202-828-0850
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, $0.01 par value DHR New York Stock Exchange
1.700% Senior Notes due 2024 DHR 24 New York Stock Exchange
0.200% Senior Notes due 2026 DHR/26 New York Stock Exchange
2.100% Senior Notes due 2026 DHR 26 New York Stock Exchange
1.200% Senior Notes due 2027 DHR/27 New York Stock Exchange
0.450% Senior Notes due 2028 DHR/28 New York Stock Exchange
2.500% Senior Notes due 2030 DHR 30 New York Stock Exchange
0.750% Senior Notes due 2031 DHR/31 New York Stock Exchange
1.350% Senior Notes due 2039 DHR/39 New York Stock Exchange
1.800% Senior Notes due 2049 DHR/49 New York Stock Exchange

-- 1 of 49 --

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was
required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be
submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the
registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a
smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated
filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer ☒ Accelerated Filer ☐
Non-accelerated Filer ☐ Smaller Reporting Company ☐
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act) Yes ☐ No ☒
The number of shares of common stock outstanding at October 19, 2023 was 738,927,107.

-- 2 of 49 --

DANAHER CORPORATION
INDEX
FORM 10-Q
Page
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Condensed Balance Sheets 1
Consolidated Condensed Statements of Earnings 2
Consolidated Condensed Statements of Comprehensive Income 3
Consolidated Condensed Statements of Stockholders’ Equity 4
Consolidated Condensed Statements of Cash Flows 5
Notes to Consolidated Condensed Financial Statements 6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 24
Item 3. Quantitative and Qualitative Disclosures About Market Risk 42
Item 4. Controls and Procedures 42
PART II - OTHER INFORMATION
Item 1. Legal Proceedings 43
Item 1A. Risk Factors 43
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 43
Item 5. Other Information 43
Item 6. Exhibits 44
Signatures 46

-- 3 of 49 --

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
($ in millions, except per share amount)
(unaudited)
September 29, 2023 December 31, 2022
ASSETS
Current assets:
Cash and equivalents $ 12,277 $ 5,995
Trade accounts receivable, less allowance for doubtful accounts of $136 and
$126, respectively 4,201 4,918
Inventories:
Finished goods 1,447 1,504
Work in process 497 473
Raw materials 1,080 1,133
Total inventories 3,024 3,110
Prepaid expenses and other current assets 1,703 1,860
Total current assets 21,205 15,883
Property, plant and equipment, net of accumulated depreciation of $4,122 and
$3,893, respectively 4,302 3,956
Other long-term assets 4,286 4,459
Goodwill 39,155 39,752
Other intangible assets, net 18,786 20,300
Total assets $ 87,734 $ 84,350
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Notes payable and current portion of long-term debt $ 2,547 $ 591
Trade accounts payable 1,894 2,296
Accrued expenses and other liabilities 4,926 5,502
Total current liabilities 9,367 8,389
Other long-term liabilities 6,439 6,785
Long-term debt 19,513 19,086
Stockholders’ equity:
Preferred stock, no par value, 15.0 million shares authorized; no shares issued
and outstanding as of September 29, 2023; 1.72 million shares of 5.00%
Mandatory Convertible Preferred Stock, Series B, issued and outstanding as of
December 31, 2022 — 1,668
Common stock - $0.01 par value, 2.0 billion shares authorized; 880.2 million
issued and 738.9 million outstanding as of September 29, 2023; 869.3 million
issued and 728.3 million outstanding as of December 31, 2022 9 9
Additional paid-in capital 14,085 12,072
Retained earnings 42,272 39,205
Accumulated other comprehensive income (loss) (3,959) (2,872)
Total Danaher stockholders’ equity 52,407 50,082
Noncontrolling interests 8 8
Total stockholders’ equity 52,415 50,090
Total liabilities and stockholders’ equity $ 87,734 $ 84,350
See the accompanying Notes to the Consolidated Condensed Financial Statements.
Table of Contents
1

-- 4 of 49 --

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
($ and shares in millions, except per share amounts)
(unaudited)
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Sales $ 6,873 $ 7,663 $ 21,197 $ 23,102
Cost of sales (2,873) (3,079) (8,786) (9,092)
Gross profit 4,000 4,584 12,411 14,010
Operating costs:
Selling, general and administrative
expenses (2,145) (2,149) (6,486) (6,326)
Research and development
expenses (417) (420) (1,264) (1,292)
Operating profit 1,438 2,015 4,661 6,392
Nonoperating income (expense):
Other income (expense), net (47) (51) (52) (158)
Interest expense (73) (42) (208) (147)
Interest income 79 9 186 12
Earnings before income taxes 1,397 1,931 4,587 6,099
Income taxes (268) (359) (902) (1,122)
Net earnings 1,129 1,572 3,685 4,977
Mandatory convertible preferred stock
dividends — (21) (21) (84)
Net earnings attributable to common
stockholders $ 1,129 $ 1,551 $ 3,664 $ 4,893
Net earnings per common share:
Basic $ 1.53 $ 2.13 $ 4.98 (a) $ 6.76
Diluted $ 1.51 $ 2.10 $ 4.94 $ 6.67 (a)
Average common stock and common
equivalent shares outstanding:
Basic 739.4 728.5 735.4 723.8
Diluted 745.9 737.4 742.1 737.0
(a) Net earnings per common share amounts for the relevant three-month periods do not add to the nine-month period amount due to rounding.
See the accompanying Notes to the Consolidated Condensed Financial Statements.
Table of Contents
2

-- 5 of 49 --

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
($ in millions)
(unaudited)
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Net earnings $ 1,129 $ 1,572 $ 3,685 $ 4,977
Other comprehensive income (loss), net of
income taxes:
Foreign currency translation adjustments (303) (1,039) (982) (2,824)
Pension and postretirement plan benefit
adjustments 1 7 1 28
Cash flow hedge adjustments (81) (77) (106) (31)
Total other comprehensive income (loss), net
of income taxes (383) (1,109) (1,087) (2,827)
Comprehensive income $ 746 $ 463 $ 2,598 $ 2,150
See the accompanying Notes to the Consolidated Condensed Financial Statements.
Table of Contents
3

-- 6 of 49 --

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY
($ in millions)
(unaudited)
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Preferred stock:
Balance, beginning of period $ — $ 1,668 $ 1,668 $ 3,268
Conversion of Mandatory Convertible
Preferred Stock to common stock — — (1,668) (1,600)
Balance, end of period $ — $ 1,668 $ — $ 1,668
Common stock:
Balance, beginning and end of period $ 9 $ 9 $ 9 $ 9
Additional paid-in capital:
Balance, beginning of period $ 13,939 $ 11,854 $ 12,072 $ 10,090
Common stock-based award 146 131 345 309
Common stock issued in connection
with Mandatory Convertible Preferred
Stock conversions — — 1,668 1,600
Acquisition of noncontrolling interests — — — (14)
Balance, end of period $ 14,085 $ 11,985 $ 14,085 $ 11,985
Retained earnings:
Balance, beginning of period $ 41,344 $ 35,808 $ 39,205 $ 32,827
Net earnings 1,129 1,572 3,685 4,977
Common stock dividends declared (201) (182) (597) (543)
Mandatory Convertible Preferred
Stock dividends declared — (21) (21) (84)
Balance, end of period $ 42,272 $ 37,177 $ 42,272 $ 37,177
Accumulated other comprehensive income
(loss):
Balance, beginning of period $ (3,576) $ (2,745) $ (2,872) $ (1,027)
Other comprehensive income (loss) (383) (1,109) (1,087) (2,827)
Balance, end of period $ (3,959) $ (3,854) $ (3,959) $ (3,854)
Noncontrolling interests:
Balance, beginning of period $ 8 $ 7 $ 8 $ 10
Change in noncontrolling interests — 1 — (2)
Balance, end of period $ 8 $ 8 $ 8 $ 8
Total stockholders’ equity, end of period $ 52,415 $ 46,993 $ 52,415 $ 46,993
See the accompanying Notes to the Consolidated Condensed Financial Statements.
Table of Contents
4

-- 7 of 49 --

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
($ in millions)
(unaudited)
Nine-Month Period Ended
September 29, 2023 September 30, 2022
Cash flows from operating activities:
Net earnings $ 3,685 $ 4,977
Noncash items:
Depreciation 526 537
Amortization of intangible assets 1,147 1,120
Stock-based compensation expense 280 270
Investment (gains) losses 58 186
Change in trade accounts receivable, net 709 (134)
Change in inventories (25) (729)
Change in trade accounts payable (399) (180)
Change in prepaid expenses and other assets 331 (104)
Change in accrued expenses and other liabilities (767) 35
Net cash provided by operating activities 5,545 5,978
Cash flows from investing activities:
Cash paid for acquisitions — (304)
Payments for additions to property, plant and equipment (981) (823)
Proceeds from sales of property, plant and equipment 8 9
Payments for purchases of investments (152) (354)
Proceeds from sales of investments 33 18
All other investing activities 28 36
Total cash used in investing activities (1,064) (1,418)
Cash flows from financing activities:
Proceeds from the issuance of common stock in connection with stock-based
compensation, net 51 15
Payment of dividends (621) (615)
Net borrowings (maturities longer than 90 days) 2,605 —
Net repayments of borrowings (maturities of 90 days or less) (9) (719)
Net repayments of borrowings (maturities longer than 90 days) — (265)
All other financing activities (53) (80)
Total cash provided by (used in) financing activities 1,973 (1,664)
Effect of exchange rate changes on cash and equivalents (172) (332)
Net change in cash and equivalents 6,282 2,564
Beginning balance of cash and equivalents 5,995 2,586
Ending balance of cash and equivalents $ 12,277 $ 5,150
Supplemental disclosures:
Cash interest payments $ 289 $ 250
Cash income tax payments 1,170 1,094
See the accompanying Notes to the Consolidated Condensed Financial Statements.
Table of Contents
5

-- 8 of 49 --

DANAHER CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(unaudited)
NOTE 1. GENERAL
The Consolidated Condensed Financial Statements included herein have been prepared by Danaher Corporation
(“Danaher” or the “Company”) without audit, pursuant to the rules and regulations of the Securities and Exchange
Commission (“SEC”). In this quarterly report, the terms “Danaher” or the “Company” refer to Danaher Corporation,
Danaher Corporation and its consolidated subsidiaries, or the consolidated subsidiaries of Danaher Corporation, as the
context requires. Certain information and footnote disclosures normally included in financial statements prepared in
accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or
omitted pursuant to SEC rules and regulations; however, the Company believes that the disclosures are adequate to
make the information presented not misleading. The Consolidated Condensed Financial Statements included herein
should be read in conjunction with the financial statements as of and for the year ended December 31, 2022 and the
Notes thereto included in the Company’s 2022 Annual Report on Form 10-K filed on February 22, 2023 (the “2022 Annual
Report”).
In the opinion of the Company, the accompanying financial statements contain all adjustments (consisting of only normal
recurring accruals) necessary to present fairly the financial position of the Company as of September 29, 2023 and
December 31, 2022, its results of operations for the three and nine-month periods ended September 29, 2023 and
September 30, 2022 and its cash flows for each of the nine-month periods then ended.
There have been no changes to the Company’s significant accounting policies described in the Company’s 2022 Annual
Report that have a material impact on the Company’s Consolidated Condensed Financial Statements and the related
Notes. Reclassifications of certain prior year amounts have been made to conform to the current year presentation.
Accounting Standards Recently Adopted—In August 2023, the Financial Accounting Standards Board (“FASB”) issued
Accounting Standards Update (“ASU”) 2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60):
Recognition and Initial Measurement. The ASU requires that a joint venture apply a new basis of accounting upon
formation in which the joint venture will recognize and initially measure its assets and liabilities at fair value (with
exceptions to fair value measurement that are consistent with the business combinations guidance). The ASU is effective
prospectively for all joint venture formations with a formation date on or after January 1, 2025, with early adoption
permitted. The Company early adopted the ASU effective September 30, 2023 on a prospective basis.
Operating Leases—As of September 29, 2023 and December 31, 2022, operating lease right-of-use assets where the
Company was the lessee were approximately $1.0 billion and are included within other long-term assets in the
accompanying Consolidated Condensed Balance Sheets. The associated operating lease liabilities were approximately
$1.1 billion as of September 29, 2023 and December 31, 2022, and are included in accrued expenses and other liabilities
and other long-term liabilities.
NOTE 2. PENDING ACQUISITION
On August 28, 2023, the Company entered into a definitive agreement to acquire all of the outstanding shares of Abcam
plc (“Abcam”) for a cash purchase price of approximately $5.7 billion, including assumed indebtedness and net of
acquired cash (the “Abcam Acquisition”). Abcam is a leading global supplier of protein consumables, including highly
validated antibodies, reagents, biomarkers and assays to address targets in biological pathways that are critical for
advancing drug discovery, life sciences research and diagnostics. Abcam generated revenues of £362 million in 2022.
The Company expects to include the Abcam business within its Life Sciences segment. The transaction is subject to
customary closing conditions, including receipt of applicable regulatory approvals and Abcam shareholder approval.
The Company expects to finance the Abcam Acquisition using cash on hand and/or the proceeds from the issuance of
commercial paper.
NOTE 3. ENVIRONMENTAL & APPLIED SOLUTIONS SEPARATION
On September 30, 2023 (the “Distribution Date”), the Company completed the separation (the “Separation”) of its former
Environmental & Applied Solutions business by distributing to Danaher stockholders on a pro rata basis all of the issued
and outstanding common stock of Veralto Corporation (“Veralto”), the entity Danaher incorporated to hold such
businesses. To effect the Separation, Danaher distributed to its stockholders one share of Veralto common stock for every
three shares of Danaher common stock outstanding as of September 13, 2023, the record date for the distribution.
Fractional shares of Veralto common stock that otherwise would have been distributed were aggregated and sold into the
public market and the proceeds distributed to Danaher stockholders who otherwise would have received fractional shares
of Veralto common stock.
Table of Contents
6

-- 9 of 49 --

In preparation for the Separation, in September 2023 Veralto issued approximately $2.6 billion in debt securities (refer to
Note 11). The proceeds of these issuances were used to fund the approximately $2.6 billion net cash distributions Veralto
made to Danaher prior to the Distribution Date. In accordance with the applicable tax rules, Danaher intends to use a
portion of the cash distribution proceeds it received from Veralto to meet upcoming commercial paper and bond maturities
and to use the balance of the proceeds to partially fund certain of the Company’s regular, quarterly cash dividends to
shareholders.
As the disposition occurred during the fourth quarter of 2023, the Company will classify Veralto as a discontinued
operation in its historical financial statements beginning with the fourth quarter of 2023. The Environmental & Applied
Solutions business had sales for the year ended December 31, 2022 of approximately $4.8 billion. Below is a summary of
the Environmental & Applied Solutions business' sales and operating profit ($ in millions):
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Sales $ 1,249 $ 1,208 $ 3,712 $ 3,593
Operating profit 286 286 887 829
The Company incurred separation costs of $36 million ($31 million after-tax) and $101 million ($90 million after-tax) in the
three and nine-month periods ended September 29, 2023, respectively, related to preparation for the separation of the
Company’s Environmental & Applied Solutions business primarily related to professional fees for legal, tax, finance,
banking and information technology services and duplicative general and administrative costs.
In connection with the Separation, Danaher and Veralto entered into various agreements to effect the Separation and
provide a framework for their relationship after the Separation, including a separation and distribution agreement,
transition services agreement, an employee matters agreement, a tax matters agreement, an intellectual property matters
agreement and a Danaher Business System (“DBS”) license agreement. These agreements provide for the allocation
between Danaher and Veralto of assets, employees, liabilities and obligations (including investments, property and
employee benefits and tax-related assets and liabilities) attributable to periods prior to, at and after Veralto’s separation
from Danaher and will govern certain relationships between Danaher and Veralto after the Separation.
NOTE 4. NET EARNINGS PER COMMON SHARE
Basic net earnings per common share (“EPS”) is calculated by taking net earnings less the Mandatory Convertible
Preferred Stock (“MCPS”) dividends divided by the weighted average number of common shares outstanding for the
applicable period. Diluted net EPS is computed by taking net earnings less the MCPS dividends divided by the weighted
average number of common shares outstanding increased by the number of additional shares that would have been
outstanding had the potentially dilutive common shares been issued and reduced by the number of shares the Company
could have repurchased with the proceeds from the issuance of the potentially dilutive shares. For the three-month
periods ended September 29, 2023 and September 30, 2022, approximately 2.5 million and 538 thousand options,
respectively, and for the nine-month periods ended September 29, 2023 and September 30, 2022, approximately 3.2
million and 1.1 million options, respectively, to purchase shares were excluded from the diluted EPS calculation, as the
impact of their inclusion would have been anti-dilutive. Basic and diluted EPS are computed independently for each
quarter and year-to-date period, and each period involves the use of different weighted-average share count figures. As a
result, and after factoring the effect of rounding to the nearest cent per share, the sum of prior quarterly EPS figures may
not equal year-to-date EPS.
The impact of the MCPS Series B calculated under the if-converted method was anti-dilutive for the nine-month period
ended September 29, 2023 and the three and nine-month periods ended September 30, 2022, and as such 3.4 million
shares for the nine-month period ended September 29, 2023 and 8.6 million for both the three and nine-month periods
ended September 30, 2022 underlying the MCPS Series B were excluded from the calculation of diluted EPS and the
related MCPS Series B dividends of $21 million for the nine-month period ended September 29, 2023 and $21 million and
$64 million for the three and nine-month periods ended September 30, 2022, respectively, were included in the calculation
of net earnings for diluted EPS. As of April 17, 2023, all outstanding shares of the MCPS Series B converted into
8.6 million shares of the Company’s common stock.
The impact of the MCPS Series A calculated under the if-converted method was dilutive for the nine-month period ended
September 30, 2022, and as such 4.0 million shares underlying the MCPS Series A were included in the calculation of
diluted EPS. The related MCPS Series A dividends of $20 million for the nine-month period ended September 30, 2022
were excluded from the calculation of net earnings for diluted EPS. On April 15, 2022, all outstanding shares of the MCPS
Series A converted into 11.0 million shares of the Company’s common stock. Refer to Note 15 for additional information
about the MCPS Series A and B conversions.
Table of Contents
7

-- 10 of 49 --

Information related to the calculation of net earnings per common share is summarized as follows ($ and shares in
millions, except per share amounts):
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Numerator:
Net earnings $ 1,129 $ 1,572 $ 3,685 $ 4,977
MCPS dividends — (21) (21) (84)
Net earnings attributable to common
stockholders for Basic EPS 1,129 1,551 3,664 4,893
Adjustment for MCPS dividends for dilutive
MCPS — — — 20
Net earnings attributable to common
stockholders after assumed conversions for
Diluted EPS $ 1,129 $ 1,551 $ 3,664 $ 4,913
Denominator:
Weighted average common shares
outstanding used in Basic EPS 739.4 728.5 735.4 723.8
Incremental common shares from:
Assumed exercise of dilutive options and
vesting of dilutive restricted stock units
(“RSUs”) and performance stock units
(“PSUs”) 6.5 8.9 6.7 9.2
Weighted average MCPS converted
shares — — — 4.0
Weighted average common shares
outstanding used in Diluted EPS 745.9 737.4 742.1 737.0
Basic EPS $ 1.53 $ 2.13 $ 4.98 $ 6.76
Diluted EPS $ 1.51 $ 2.10 $ 4.94 $ 6.67
Table of Contents
8

-- 11 of 49 --

NOTE 5. REVENUE
The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the
three and nine-month periods ended September 29, 2023 and September 30, 2022 ($ in millions). Sales taxes and other
usage-based taxes collected from customers are excluded from revenue.
Biotechnology Life Sciences Diagnostics
Environmental &
Applied
Solutions Total
For the Three-Month Period Ended
September 29, 2023:
Geographical region:
North America(a) $ 593 $ 728 $ 1,054 $ 599 $ 2,974
Western Europe 508 356 334 269 1,467
Other developed markets(b) 78 117 105 30 330
High-growth markets(c) 485 505 761 351 2,102
Total $ 1,664 $ 1,706 $ 2,254 $ 1,249 $ 6,873
Revenue type:
Recurring $ 1,390 $ 1,062 $ 1,986 $ 744 $ 5,182
Nonrecurring 274 644 268 505 1,691
Total $ 1,664 $ 1,706 $ 2,254 $ 1,249 $ 6,873
For the Three-Month Period Ended
September 30, 2022:
Geographical region:
North America(a) $ 723 $ 785 $ 1,397 $ 575 $ 3,480
Western Europe 599 314 388 240 1,541
Other developed markets(b) 71 118 122 28 339
High-growth markets(c) 660 506 772 365 2,303
Total $ 2,053 $ 1,723 $ 2,679 $ 1,208 $ 7,663
Revenue type:
Recurring $ 1,662 $ 1,038 $ 2,396 $ 729 $ 5,825
Nonrecurring 391 685 283 479 1,838
Total $ 2,053 $ 1,723 $ 2,679 $ 1,208 $ 7,663
Table of Contents
9

-- 12 of 49 --

Biotechnology Life Sciences Diagnostics
Environmental &
Applied
Solutions Total
For the Nine-Month Period Ended
September 29, 2023:
Geographical region:
North America(a) $ 1,822 $ 2,193 $ 3,160 $ 1,748 $ 8,923
Western Europe 1,839 1,095 1,119 830 4,883
Other developed markets(b) 229 369 322 90 1,010
High-growth markets(c) 1,523 1,554 2,260 1,044 6,381
Total $ 5,413 $ 5,211 $ 6,861 $ 3,712 $ 21,197
Revenue type:
Recurring $ 4,435 $ 3,205 $ 6,056 $ 2,210 $ 15,906
Nonrecurring 978 2,006 805 1,502 5,291
Total $ 5,413 $ 5,211 $ 6,861 $ 3,712 $ 21,197
For the Nine-Month Period Ended
September 30, 2022:
Geographical region:
North America(a) $ 2,303 $ 2,301 $ 3,938 $ 1,674 $ 10,216
Western Europe 1,938 982 1,365 775 5,060
Other developed markets(b) 244 366 361 92 1,063
High-growth markets(c) 2,050 1,441 2,220 1,052 6,763
Total $ 6,535 $ 5,090 $ 7,884 $ 3,593 $ 23,102
Revenue type:
Recurring $ 5,267 $ 3,143 $ 7,067 $ 2,138 $ 17,615
Nonrecurring 1,268 1,947 817 1,455 5,487
Total $ 6,535 $ 5,090 $ 7,884 $ 3,593 $ 23,102
(a) The Company defines North America as the United States and Canada.
(b) The Company defines other developed markets as Japan, Australia and New Zealand.
(c) The Company defines high-growth markets as developing markets of the world experiencing accelerated growth, over extended periods, in
gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America (including Mexico) and Asia
(with the exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets of the world that are not
high-growth markets.
The Company sells equipment to customers as well as consumables and services, some of which customers purchase on
a recurring basis. Consumables sold for use with the equipment sold by the Company are typically critical to the use of
the equipment and are typically used on a one-time or limited basis, requiring frequent replacement in the customer’s
operating cycle. Examples of these consumables include reagents used in diagnostic tests, chromatography resins used
for research and bioprocessing, filters used in filtration, separation and purification processes and (prior to the Separation)
cartridges for marking and coding equipment. Additionally, some of the Company’s consumables are used on a
standalone basis, such as custom nucleic acids, genomics solutions and (prior to the Separation) water treatment
solutions. The Company separates its goods and services between those typically sold to a customer on a recurring basis
and those typically sold to a customer on a nonrecurring basis. Recurring revenue includes revenue from consumables,
services and operating-type leases (“OTLs”). Nonrecurring revenue includes sales of equipment and sales-type leases
(“STLs”). OTLs and STLs are included in the above revenue amounts. For the three-month periods ended
September 29, 2023 and September 30, 2022, lease revenue was $125 million and $120 million, respectively. For the
nine-month periods ended September 29, 2023 and September 30, 2022, lease revenue was $363 million and $361
million, respectively.
Remaining performance obligations related to Topic 606, Revenue from Contracts with Customers, represent the
aggregate transaction price allocated to performance obligations with an original contract term greater than one year
which are fully or partially unsatisfied at the end of the period. As of September 29, 2023, the aggregate amount of the
transaction price allocated to remaining performance obligations was approximately $4.9 billion. The Company expects to
recognize revenue on approximately 51% of the remaining performance obligations over the next 12 months, 27% over
the subsequent 12 months, and the remainder recognized thereafter.
Table of Contents
10

-- 13 of 49 --

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables
(“contract assets”) and deferred revenue, customer deposits and billings in excess of revenue recognized (“contract
liabilities”) on the Consolidated Condensed Balance Sheets.
Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract terms and
conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in billing occurring
subsequent to revenue recognition resulting in contract assets. Contract assets are generally classified as other current
assets in the Consolidated Condensed Balance Sheets. The balance of contract assets as of September 29, 2023 and
December 31, 2022 was $63 million and $90 million, respectively.
The Company often receives cash payments from customers in advance of the Company’s performance resulting in
contract liabilities that are classified as either current or long-term in the Consolidated Condensed Balance Sheets based
on the timing of when the Company expects to recognize revenue. As of both September 29, 2023 and December 31,
2022, contract liabilities were approximately $1.9 billion, and are included within accrued expenses and other liabilities
and other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. Revenue recognized
during both the nine-month periods ended September 29, 2023 and September 30, 2022 that was included in the contract
liability balance on December 31, 2022 and December 31, 2021, respectively, was approximately $1.2 billion. Contract
assets and liabilities are reported on a net basis on the accompanying Consolidated Condensed Balance Sheets on a
contract-by-contract basis at the end of each reporting period.
NOTE 6. SEGMENT INFORMATION
The Company operates and reports its results in business segments consisting of the Biotechnology, Life Sciences,
Diagnostics, and (prior to the Separation) Environmental & Applied Solutions segments. When determining the reportable
segments, the Company aggregated operating segments based on their similar economic and operating characteristics.
Operating profit represents total revenues less operating expenses, excluding nonoperating income and expense, interest
and income taxes. Operating profit amounts in the Other segment consist of unallocated corporate costs, including
separation costs related to preparation for the separation of the Company’s Environmental & Applied Solutions business
of $36 million and $101 million in the three and nine-month periods ended September 29, 2023, respectively, and other
costs not considered part of management’s evaluation of reportable segment operating performance. Intersegment
amounts are not significant and are eliminated to arrive at consolidated totals.
Segment results are shown below ($ in millions):
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Sales:
Biotechnology $ 1,664 $ 2,053 $ 5,413 $ 6,535
Life Sciences 1,706 1,723 5,211 5,090
Diagnostics 2,254 2,679 6,861 7,884
Environmental & Applied Solutions 1,249 1,208 3,712 3,593
Total $ 6,873 $ 7,663 $ 21,197 $ 23,102
Operating profit:
Biotechnology $ 417 $ 691 $ 1,493 $ 2,315
Life Sciences 313 354 974 1,022
Diagnostics 539 761 1,640 2,447
Environmental & Applied Solutions 286 286 887 829
Other (117) (77) (333) (221)
Total $ 1,438 $ 2,015 $ 4,661 $ 6,392
NOTE 7. INCOME TAXES
The following table summarizes the Company’s effective tax rate:
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Effective tax rate 19.2 % 18.6 % 19.7 % 18.4 %
Table of Contents
11

-- 14 of 49 --

The Company operates globally, including in certain jurisdictions with lower tax rates than the United States (“U.S.”)
federal statutory rate. Therefore, the impact of operating in such jurisdictions contributes to a lower effective tax rate
compared to the U.S. federal statutory tax rate.
The effective tax rate for the three-month period ended September 29, 2023 differs from the U.S. federal statutory rate of
21.0% due to the geographic mix of earnings described above. Discrete tax benefits from excess tax benefits from stock-
based compensation were offset by charges related to tax costs related to the separation of the Environmental & Applied
Solutions business and changes in estimates associated with prior period uncertain tax positions.
The effective tax rate for the nine-month period ended September 29, 2023 differs from the U.S. federal statutory rate of
21.0% principally due to the geographic mix of earnings described above, partially offset by net discrete tax charges of
$13 million. Net discrete tax charges related primarily to tax costs related to the separation of the Environmental &
Applied Solutions business, tax costs related to legal and operational actions taken to realign certain businesses and
changes in estimates associated with prior period uncertain tax positions, partially offset by excess tax benefits from
stock-based compensation and interest on prior year tax refunds. The net discrete charges increased the effective tax
rate by 0.3% for the nine-month period ended September 29, 2023.
The effective tax rate for the three-month period ended September 30, 2022 differs from the U.S. federal statutory rate of
21.0% principally due to the geographic mix of earnings described above and net discrete benefits of $3 million related
primarily to excess tax benefits from stock-based compensation, partially offset by changes in estimates associated with
prior period uncertain tax positions. The net discrete benefits reduced the effective tax rate by 0.2% for the three-month
period ended September 30, 2022.
The effective tax rate for the nine-month period ended September 30, 2022 differs from the U.S. federal statutory rate of
21.0% principally due the geographic mix of earnings described above and net discrete benefits of $52 million related
primarily to excess tax benefits from stock-based compensation and changes in estimates associated with prior period
uncertain tax positions. The net discrete benefits reduced the effective tax rate by 0.9% for the nine-month period ended
September 30, 2022.
In the fourth quarter of 2022, the U.S. Internal Revenue Service (“IRS”) proposed significant adjustments to the
Company’s taxable income for the years 2016 through 2018 with respect to the deferral of tax on certain premium income
related to the Company’s self-insurance programs. For income tax purposes, the recognition of premium income has
been deferred in accordance with U.S. tax laws related to insurance. The IRS challenged the deferral of premium income
for certain types of the Company’s self-insurance policies. The proposed adjustments would have increased the
Company’s taxable income over the 2016 through 2018 periods by approximately $2.5 billion. In the first quarter of 2023,
the Company settled these proposed adjustments with the IRS, although the audit is still open with respect to other
matters for the 2016 through 2018 period. The impact of the settlement with respect to the Company’s self-insurance
policies was not material to the Company’s financial statements, including cash flows and the effective tax rate. As the
settlement with the IRS was specific to the audit period, the settlement does not preclude the IRS from proposing similar
adjustments to the Company’s self-insurance programs with respect to periods subsequent to 2018. Management
believes the positions the Company has taken in its U.S. tax returns are in accordance with the relevant tax laws.
For a description of the Company’s significant tax matters, reference is made to the financial statements as of and for the
year ended December 31, 2022 and Note 7 thereto included in the Company’s 2022 Annual Report.
NOTE 8. OTHER INCOME (EXPENSE), NET
The following sets forth the components of the Company’s other income (expense), net ($ in millions):
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Other components of net periodic benefit
costs $ 1 $ 13 $ 6 $ 28
Investment gains (losses):
Realized investment gains (losses) 120 27 120 91
Unrealized investment gains (losses) (168) (91) (178) (277)
Total investment gains (losses) (48) (64) (58) (186)
Total other income (expense), net $ (47) $ (51) $ (52) $ (158)
Table of Contents
12

-- 15 of 49 --

Other Components of Net Periodic Benefit Costs
The Company disaggregates the service cost component of net periodic benefit costs of noncontributory defined benefit
pension plans and other postretirement employee benefit plans and presents the other components of net periodic benefit
costs in other income (expense), net. These other components of net periodic benefit costs include the assumed rate of
return on plan assets, partially offset by amortization of actuarial losses and interest. The Company’s net periodic benefit
costs for the nine-month period ended September 30, 2022 included a settlement loss of $10 million ($9 million after-tax)
as a result of the transfer of a portion of its non-U.S. pension liabilities related to one defined benefit plan to a third-party.
Investment Gains (Losses)
The Company estimates the fair value of its investments in equity securities using the Fair Value Alternative and records
adjustments to fair value within net earnings. Additionally, the Company is a limited partner in partnerships that invest
primarily in early-stage companies. While the partnerships record these investments at fair value, the Company’s
investments in the partnerships are accounted for under the equity method of accounting. The investment gains (losses)
include realized and unrealized gains and losses related to changes in the fair value of the Company’s investments in
equity securities and the Company’s equity in earnings of the partnerships that reflect the changes in fair value of the
investments of the partnerships, and related management fees and operating expenses. In addition, the Company
recorded an impairment of $46 million ($35 million after-tax) related to equity method investments that is reflected in
unrealized investment gains (losses) for the nine-month period ended September 29, 2023.
NOTE 9. GOODWILL AND OTHER INTANGIBLE ASSETS
The following is a rollforward of the Company’s goodwill ($ in millions):
Balance, December 31, 2022 $ 39,752
Adjustments due to finalization of purchase price allocations (2)
Foreign currency translation and other (595)
Balance, September 29, 2023 $ 39,155
The carrying value of goodwill by segment is summarized as follows ($ in millions):
September 29, 2023 December 31, 2022
Biotechnology $ 21,643 $ 22,087
Life Sciences 8,227 8,314
Diagnostics 6,805 6,875
Environmental & Applied Solutions 2,480 2,476
Total $ 39,155 $ 39,752
The Company has not identified any “triggering” events which indicate an impairment of goodwill in 2023.
The Company reviews identified intangible assets for impairment whenever events or changes in circumstances indicate
that the related carrying amounts may not be recoverable. The Company identified impairment triggers during the second
and third quarters of 2023 and the second quarter of 2022 which resulted in the impairment charges of certain long-lived
assets, including technology, customer relationships and trade names. The Company recorded impairment charges
totaling $6 million and $40 million in the three and nine-month periods ended September 29, 2023, respectively, and $9
million in the nine-month period ended September 30, 2022 related to these long-lived assets. In addition, during the
nine-month period ended September 29, 2023, the Company recorded a $14 million impairment related to a facility.
NOTE 10. FAIR VALUE MEASUREMENTS
Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where
the Company’s assets and liabilities are required to be carried at fair value and provide for certain disclosures related to
the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy
prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for
identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted
prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or
liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by,
observable market data through correlation. Level 3 inputs are unobservable inputs based on the Company’s
assumptions. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input
that is significant to the fair value measurement in its entirety.
Table of Contents
13

-- 16 of 49 --

A summary of financial assets that are measured at fair value on a recurring basis were as follows ($ in millions):
Balance Quoted Prices in Active
Market (Level 1) Significant Other
Observable Inputs (Level 2) Significant Unobservable
Inputs (Level 3)
September
29, 2023 December
31, 2022 September
29, 2023 December
31, 2022 September
29, 2023 December
31, 2022 September
29, 2023 December
31, 2022
Assets:
Available-for-sale
debt securities $ 4 $ 11 $ — $ — $ 4 $ 11 $ — $ —
Investment in equity
securities 444 315 131 16 — — — —
Cross-currency
swap derivative
contracts 547 653 — — 547 653 — —
Available-for-sale debt securities, which are included in other long-term assets in the accompanying Consolidated
Condensed Balance Sheets, are measured at fair value using quoted prices reported by investment brokers and dealers
based on the underlying terms of the security and comparison to similar securities traded on an active market. As of
September 29, 2023 and December 31, 2022, available-for-sale debt securities primarily included U.S. Treasury Notes
and corporate debt securities.
The Company’s investments in equity securities consist of investments in publicly traded equity securities and investments
in non-marketable equity securities. The publicly traded securities are classified as Level 1 in the fair value hierarchy as
they are measured based on quotes in active markets. For the non-marketable equity securities, the Company estimates
the fair value of the investments in equity securities based on the measurement alternative and adjusts for impairments
and observable price changes with a same or similar security from the same issuer within net earnings (the “Fair Value
Alternative”). The Company’s investments in these equity securities are not classified in the fair value hierarchy due to the
use of these measurement methods. Additionally, the Company is a limited partner in partnerships that invest primarily in
early-stage companies. While the partnerships record these investments at fair value, the Company’s investments in the
partnerships are accounted for under the equity method of accounting and are not subject to fair value measurement
disclosures noted above. As of both September 29, 2023 and December 31, 2022, the Company’s equity method
investments included investments in partnerships with a carrying value of approximately $1.5 billion. Refer to Note 8 for
additional information on gains and losses on the Company’s investments including investments in the partnerships.
The cross-currency swap derivative contracts are used to partially hedge the Company’s net investments in non-U.S.
operations against adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen,
euro and Swiss franc. The Company also uses cross-currency swap derivative contracts to hedge the exchange rate
exposure from long-term debt issuances in a foreign currency other than the functional currency of the borrower. The
cross-currency swap derivative contracts are classified as Level 2 in the fair value hierarchy as they are measured using
the income approach with the relevant interest rates and current foreign currency exchange rates and forward curves as
inputs. Refer to Note 12 for additional information.
Fair Value of Other Financial Instruments
The carrying amounts and fair values of the Company’s other financial instruments were as follows ($ in millions):
September 29, 2023 December 31, 2022
Carrying
Amount Fair Value Carrying
Amount Fair Value
Debt obligations:
Notes payable and current portion of long-term debt $ 2,547 $ 2,534 $ 591 $ 584
Long-term debt 19,513 16,245 19,086 16,079
As of September 29, 2023 and December 31, 2022, short and long-term borrowings were categorized as Level 1. The fair
value of long-term borrowings was based on quoted market prices. The difference between the fair value and the carrying
amounts of long-term borrowings is attributable to changes in market interest rates and/or the Company’s credit ratings
subsequent to the incurrence of the borrowing. The fair values of borrowings with original maturities of one year or less,
as well as cash and cash equivalents, trade accounts receivable, net and trade accounts payable generally approximate
their carrying amounts due to the short-term maturities of these instruments.
Table of Contents
14

-- 17 of 49 --

NOTE 11. FINANCING
As of September 29, 2023, the Company was in compliance with all of its debt covenants. The components of the
Company’s debt were as follows ($ in millions):
Outstanding Amount
Description and Aggregate Principal Amount September 29, 2023 December 31, 2022
Euro-denominated commercial paper (€1.9 billion)(e) $ 1,982 $ 2,013
0.5% senior unsecured bonds due 12/08/2023 (CHF 540 million) (the “2023 CHF
Bonds”)(c) 590 584
1.7% senior unsecured notes due 3/30/2024 (€900 million) (the “2024 Euronotes”)(f) 951 962
2.2% senior unsecured notes due 11/15/2024 ($700 million) (the “2024 Biopharma
Notes”)(b) 699 698
3.35% senior unsecured notes due 9/15/2025 ($500 million) (the “2025 U.S. Notes”)(f) 499 499
0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma
Euronotes”)(b) 1,317 1,333
2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”)(f) 844 854
0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”)(d) 206 234
1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”)(a) 632 639
0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma
Euronotes”)(b) 1,315 1,331
1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF
Bonds”)(c) 232 230
2.6% senior unsecured notes due 11/15/2029 ($800 million) (the “2029 Biopharma
Notes”)(b) 796 796
2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”)(f) 846 856
0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma
Euronotes”)(b) 1,841 1,863
0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”)(d) 355 404
1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma
Euronotes”)(b) 1,307 1,323
3.25% senior unsecured notes due 11/15/2039 ($900 million) (the “2039 Biopharma
Notes”)(b) 891 890
4.375% senior unsecured notes due 9/15/2045 ($500 million) (the “2045 U.S. Notes”)(f) 499 499
1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma
Euronotes”)(b) 784 794
3.4% senior unsecured notes due 11/15/2049 ($900 million) (the “2049 Biopharma
Notes”)(b) 890 889
2.6% senior unsecured notes due 10/01/2050 ($1.0 billion) (the “2050 U.S. Notes”)(f) 981 981
2.8% senior unsecured notes due 12/10/2051 ($1.0 billion) (the “2051 U.S. Notes”)(f) 984 984
Other 15 21
Subtotal $ 19,456 $ 19,677
Veralto debt:
5.50% senior unsecured bonds due 9/18/2026 ($700 million) (the “2026 Veralto
Bonds”)(g) 695 —
5.35% senior unsecured bonds due 9/18/2028 ($700 million) (the “2028 Veralto
Bonds”)(g) 694 —
4.15% senior unsecured bonds due 9/19/2031 (€500 million) (the “2031 Veralto
Bonds”)(g) 523 —
5.45% senior unsecured bonds due 9/18/2033 ($700 million) (the “2033 Veralto
Bonds”)(g) 692 —
Total Veralto debt $ 2,604 $ —
Total debt 22,060 19,677
Less: currently payable (2,547) (591)
Long-term debt $ 19,513 $ 19,086
(a) Issued by DH Europe Finance S.A. (“Danaher International”).
(b) Issued by DH Europe Finance II S.a.r.l. (“Danaher International II”).
(c) Issued by DH Switzerland Finance S.A. (“Danaher Switzerland”).
(d) Issued by DH Japan Finance S.A. (“Danaher Japan”).
(e) Issued by Danaher Corporation or Danaher International II.
(f) Issued by Danaher Corporation.
(g) Issued by Veralto Corporation.
Table of Contents
15

-- 18 of 49 --

Debt discounts, premiums and debt issuance costs totaled $135 million and $118 million as of September 29, 2023 and
December 31, 2022, respectively, and have been netted against the aggregate principal amounts of the related debt in the
components of debt table above. For additional details regarding the Company’s debt financing, refer to Note 14 of the
Company’s financial statements as of and for the year ended December 31, 2022 included in the Company’s 2022 Annual
Report.
The Company has historically satisfied short-term liquidity needs that are not met through operating cash flow and
available cash primarily through issuances of commercial paper under its U.S. dollar and euro-denominated commercial
paper programs.
As of September 29, 2023, borrowings outstanding under the Company’s euro-denominated commercial paper program
had a weighted average annual interest rate of 4.0% and a weighted average remaining maturity of approximately 38
days.
Revolving Credit Facility
On August 11, 2023, the Company replaced its existing $5.0 billion unsecured, multiyear revolving credit facility with a
third amended and restated $5.0 billion unsecured, multiyear revolving credit facility (the “Credit Facility”) with a syndicate
of lenders. The Credit Facility expires on August 11, 2028, subject to a one-year extension option at the request of
Danaher and with the consent of the lenders. The Credit Facility also contains an expansion option permitting Danaher to
request up to five increases of up to an aggregate additional $2.5 billion from lenders that elect to make such increase
available, upon the satisfaction of certain conditions. No borrowings were outstanding under the existing credit facility at
the time it was replaced with the Credit Facility.
Borrowings under the Credit Facility bear interest as follows: (i) in the case of borrowings denominated in U.S. dollars, (1)
Term Secured Overnight Financing Rate (“SOFR”) Loans (as defined in the Credit Facility) bear interest at a variable rate
equal to the Term SOFR (as defined in the Credit Facility) plus a margin of between 58.5 and 101.5 basis points,
depending on Danaher’s long-term debt credit rating; (2) Base Rate Committed Loans and Swing Line Loans (each as
defined in the Credit Facility) bear interest at a variable rate equal to the highest of (a) the Federal funds rate (as
published by the Federal Reserve Bank of New York from time to time) plus 1/2 of 1%, (b) Bank of America’s “prime rate”
as publicly announced from time to time, (c) Term SOFR (based on one-month interest period plus 1%) and (d) 1%, plus
in each case a margin of between 0 to 1.5 basis points depending on Danaher’s long-term debt credit rating; and (ii) in the
case of borrowings denominated in an Alternative Currency (as defined in the Credit Facility), Alternative Currency Loans
and Swing Line Loans (each as defined in the Credit Facility) bear interest at the applicable variable benchmark rate plus,
in each case, a margin of between 58.5 and 101.5 basis points, depending on Danaher’s long-term debt credit rating. In
no event will Term SOFR Loans, Swing Line Loans or Alternative Currency Loans bear interest at a rate lower than 0.0%.
In addition, Danaher is required to pay a per annum facility fee of between 4.0 and 11.0 basis points (depending on
Danaher’s long-term debt credit rating) based on the aggregate commitments under the Credit Facility, regardless of
usage.
The Credit Facility requires Danaher to maintain a Consolidated Leverage Ratio (as defined in the Credit Facility) of 0.65
to 1.00 or less. Borrowings under the Credit Facility are prepayable at Danaher’s option at any time in whole or in part
without premium or penalty.
Danaher’s obligations under the Credit Facility are unsecured. Danaher has unconditionally and irrevocably guaranteed
the obligations of each of its subsidiaries in the event a subsidiary is named a borrower under the Credit Facility. The
Credit Facility contains customary representations, warranties, conditions precedent, events of default, indemnities and
affirmative and negative covenants. Danaher intends to use the Credit Facility for liquidity support for Danaher’s U.S.
dollar and euro-denominated commercial paper programs and for general corporate purposes.
Indebtedness Related to the Veralto Separation
In September 2023, the Company received net cash distributions of approximately $2.6 billion from Veralto as partial
consideration for the Company’s contribution of assets to Veralto in connection with the Separation. Veralto financed
these cash payments through the issuance of approximately $2.6 billion of debt, consisting of $700 million aggregate
principal amount of 5.50% senior unsecured bonds due 2026, $700 million aggregate principal amount of 5.35% senior
unsecured bonds due 2028, $700 million aggregate principal amount of 5.45% senior unsecured bonds due 2033 and
€500 million aggregate principal amount of 4.15% senior unsecured bonds due 2031 (collectively, the “Veralto Debt”).
Danaher initially guaranteed the Veralto Debt, and the guarantee automatically terminated effective as of the Distribution
Date. As of September 29, 2023, Veralto was a wholly-owned, consolidated subsidiary of the Company, and as a result,
the Company’s Consolidated Balance Sheet as of September 29, 2023 includes the Veralto Debt. The transfer of the
liabilities associated with the Veralto Debt, as well as all other assets and liabilities transferred to Veralto, will be reflected
in the Company's financial statements in the fourth quarter of 2023.
Table of Contents
16

-- 19 of 49 --

In addition, Veralto Corporation entered into a revolving credit agreement with a syndicate of lenders providing for a five-
year $1.5 billion unsecured revolving credit facility (the “Veralto Credit Facility”). No amounts were outstanding under the
Veralto Credit Facility at any time prior to the Separation. As of September 29, 2023, Veralto was in compliance with all
covenants under the Veralto Credit Facility.
Guarantors of Debt
The Company has guaranteed long-term debt and commercial paper issued by certain of its wholly-owned finance
subsidiaries: Danaher International, Danaher International II, Danaher Switzerland and Danaher Japan. All of the
outstanding and future securities issued by each of these entities are or will be fully and unconditionally guaranteed by the
Company and these guarantees rank on parity with the Company’s unsecured and unsubordinated indebtedness. In
addition, prior to the Separation, the Company guaranteed the long-term debt issued by Veralto Corporation. This
guarantee terminated as of the time of the Separation.
NOTE 12. HEDGING TRANSACTIONS AND DERIVATIVE FINANCIAL INSTRUMENTS
The Company uses cross-currency swap derivative contracts to partially hedge its net investments in non-U.S. operations
against adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and
Swiss franc. The cross-currency swap derivative contracts are agreements to exchange fixed-rate payments in one
currency for fixed-rate payments in another currency. These contracts effectively convert U.S. dollar-denominated bonds
to obligations denominated in Danish kroner, Japanese yen, euro and Swiss franc, and partially offset the impact of
changes in currency rates on the Company’s foreign currency denominated net investments. These contracts also reduce
the interest rate from the stated interest rates on the U.S. dollar-denominated debt to the interest rates of the swaps. The
changes in the spot rate of these instruments are recorded in accumulated other comprehensive income (loss) in
stockholders’ equity, partially offsetting the foreign currency translation adjustment of the Company’s related net
investment that is also recorded in accumulated other comprehensive income (loss). The interest income or expense
from these swaps are recorded in interest expense in the accompanying Consolidated Condensed Statements of
Earnings consistent with the classification of interest expense attributable to the underlying debt. These instruments
mature on dates ranging from September 2025 to November 2032.
The Company also uses cross-currency swap derivative contracts to hedge U.S. dollar-denominated long-term debt
issuances in a foreign subsidiary whose functional currency is the euro against adverse movements in exchange rates
between the U.S. dollar and the euro. These contracts effectively convert these U.S. dollar-denominated bonds to
obligations denominated in euro. The changes in the fair value of these instruments are recorded in accumulated other
comprehensive income (loss), with a reclassification from accumulated other comprehensive income (loss) to net earnings
to offset the remeasurement of the hedged debt that is also recorded in net earnings. The interest income or expense
from these swaps are recorded in interest expense in the accompanying Consolidated Condensed Statements of
Earnings consistent with the classification of interest expense attributable to the underlying debt. These instruments
mature on dates ranging from November 2024 to November 2049.
The Company has also issued foreign currency denominated long-term debt as partial hedges of its net investments in
foreign operations against adverse movements in exchange rates between the U.S. dollar and the euro, Japanese yen
and Swiss franc. These foreign currency denominated long-term debt issuances are designated and qualify as
nonderivative hedging instruments. Accordingly, the foreign currency translation of these debt instruments is recorded in
accumulated other comprehensive income (loss), offsetting the foreign currency translation adjustment of the Company’s
related net investment that is also recorded in accumulated other comprehensive income (loss). These instruments
mature on dates ranging from October 2023 to May 2032.
The Company used interest rate swap agreements to hedge the variability in cash flows due to changes in benchmark
interest rates related to a portion of the U.S. debt the Company issued to fund the acquisition of Cytiva and a portion of
the 2051 U.S. Notes. These contracts effectively fixed the interest rate for a portion of the Company’s U.S. dollar-
denominated debt equal to the notional amount of the swaps to the rate specified in the interest rate swap agreements
and were settled in November 2019 and December 2021, respectively. The changes in the fair value of these instruments
were recorded in accumulated other comprehensive income (loss) prior to the issuance of the debt and are subsequently
being reclassified to interest expense over the life of the related debt.
Table of Contents
17

-- 20 of 49 --

The following table summarizes the notional values as of September 29, 2023 and September 30, 2022 and pretax impact
of changes in the fair values of instruments designated as net investment hedges and cash flow hedges in accumulated
other comprehensive income (“OCI”) for the three and nine-month periods ended September 29, 2023 and September 30,
2022 ($ in millions):
Original
Notional
Amount
Notional
Amount
Outstanding
Gain (Loss)
Recognized in
OCI
Amounts
Reclassified
from OCI
For the Three-Month Period Ended September 29, 2023:
Net investment hedges:
Cross-currency contracts $ 3,875 $ 3,000 $ 28 $ —
Foreign currency denominated debt 6,179 6,179 181 —
Cash flow hedges:
Cross-currency contracts 4,000 3,300 22 (102)
Interest rate swaps 1,600 — — —
Total $ 15,654 $ 12,479 $ 231 $ (102)
For the Three-Month Period Ended September 30, 2022:
Net investment hedges:
Cross-currency contracts $ 3,875 $ 3,000 $ 127 $ —
Foreign currency denominated debt 5,522 5,522 174 —
Cash flow hedges:
Cross-currency contracts 4,000 4,000 214 (240)
Interest rate swaps 1,600 — — —
Total $ 14,997 $ 12,522 $ 515 $ (240)
For the Nine-Month Period Ended September 29, 2023:
Net investment hedges:
Cross-currency contracts $ 3,875 $ 3,000 $ (38) $ —
Foreign currency denominated debt 6,179 6,179 130 —
Cash flow hedges:
Cross-currency contracts 4,000 3,300 (68) (39)
Interest rate swaps 1,600 — — 2
Total $ 15,654 $ 12,479 $ 24 $ (37)
For the Nine-Month Period Ended September 30, 2022:
Net investment hedges:
Cross-currency contracts $ 3,875 $ 3,000 $ 394 $ —
Foreign currency denominated debt 5,522 5,522 569 —
Cash flow hedges:
Cross-currency contracts 4,000 4,000 720 (580)
Interest rate swaps 1,600 — — 2
Total $ 14,997 $ 12,522 $ 1,683 $ (578)
Gains or losses related to the net investment hedges are classified as foreign currency translation adjustments in the
schedule of changes in OCI in Note 15, as these items are attributable to the Company’s hedges of its net investment in
foreign operations. Gains or losses related to the cash flow hedges are classified as cash flow hedge adjustments in the
schedule of changes in OCI in Note 15. The amount reclassified from other comprehensive income (loss) for the cross-
currency swap derivative contracts that are cash flow hedges of the Company’s U.S. dollar-denominated debt was equal
to the remeasurement amount recorded in the three and nine-month periods on the hedged debt.
Table of Contents
18

-- 21 of 49 --

The Company did not reclassify any other deferred gains or losses related to net investment hedges or cash flow hedges
from accumulated other comprehensive income (loss) to earnings during the three and nine-month periods ended
September 29, 2023 and September 30, 2022. In addition, the Company did not have any ineffectiveness related to net
investment hedges or cash flow hedges during the three and nine-month periods ended September 29, 2023 and
September 30, 2022, and, should they arise, any ineffective portions of the hedges would be reclassified from
accumulated other comprehensive income (loss) into earnings during the period of change. The cash inflows and
outflows associated with the Company’s derivative contracts designated as net investment hedges are classified in all
other investing activities in the accompanying Consolidated Condensed Statements of Cash Flows. The cash inflows and
outflows associated with the Company’s derivative contracts designated as cash flow hedges are classified in cash flows
from operating activities in the accompanying Consolidated Condensed Statements of Cash Flows.
The Company’s derivative instruments, as well as its nonderivative debt instruments designated and qualifying as net
investment hedges, were classified in the Company’s Consolidated Condensed Balance Sheets as follows ($ in millions):
September 29, 2023 December 31, 2022
Derivative assets:
Other long-term assets $ 547 $ 653
Nonderivative hedging instruments:
Notes payable and current portion of long-term debt 2,541 —
Long-term debt 3,638 5,777
Amounts related to the Company’s derivatives expected to be reclassified from accumulated other comprehensive income
(loss) to net earnings during the next 12 months, if interest rates and foreign exchange rates remain unchanged, are not
significant.
NOTE 13. DEFINED BENEFIT PLANS
The following sets forth the components of the Company’s net periodic benefit costs of the noncontributory defined benefit
pension plans and other postretirement employee benefit plans ($ in millions):
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
U.S. pension benefits:
Service cost $ — $ — $ — $ —
Interest cost (25) (13) (73) (40)
Expected return on plan assets 31 32 94 97
Amortization of actuarial loss (3) (8) (9) (26)
Amortization of prior service cost (1) — (1) —
Net periodic pension benefit $ 2 $ 11 $ 11 $ 31
Non-U.S. pension benefits:
Service cost $ (8) $ (10) $ (24) $ (29)
Interest cost (12) (6) (37) (18)
Expected return on plan assets 10 10 28 28
Amortization of actuarial gain (loss) 2 — 6 (1)
Amortization of prior service credit — 1 1 1
Settlement losses recognized — (1) — (11)
Net periodic pension cost $ (8) $ (6) $ (26) $ (30)
Other postretirement employee benefit plans:
Service cost $ — $ — $ — $ —
Interest cost (2) (1) (5) (2)
Amortization of actuarial loss — (1) — (1)
Amortization of prior service credit 1 — 2 1
Net periodic benefit cost $ (1) $ (2) $ (3) $ (2)
Table of Contents
19

-- 22 of 49 --

The service cost component of net periodic benefit costs is presented in cost of goods sold and selling, general and
administrative expenses while the other cost components are presented in other income (expense), net. The Company’s
net periodic pension cost for the nine-month period ended September 30, 2022 included a settlement loss of $10 million
as a result of the transfer of a portion of its non-U.S. pension liabilities related to one defined benefit plan to a third-party.
Employer Contributions
During 2023, the Company’s cash contribution requirements for its U.S. and non-U.S. defined benefit pension plans are
forecasted to be approximately $10 million and $39 million, respectively. The ultimate amounts to be contributed depend
upon, among other things, legal requirements, underlying asset returns, the plan’s funded status, the anticipated tax
deductibility of the contribution, local practices, market conditions, interest rates and other factors.
NOTE 14. COMMITMENTS AND CONTINGENCIES
The Company reviews the adequacy of its legal reserves on a quarterly basis and establishes reserves for loss
contingencies that are both probable and reasonably estimable. For a further description of the Company’s litigation and
contingencies, refer to Note 18 of the Company’s financial statements as of and for the year ended December 31, 2022
included in the Company’s 2022 Annual Report.
In connection with the Separation and in accordance with the separation and distribution and related agreements Danaher
and Veralto entered into, the Company agreed to indemnify Veralto and its affiliates against certain damages and
expenses that might occur in the future. These indemnification obligations cover a variety of liabilities, including, but not
limited to, employee and tax matters.
The Company generally accrues estimated warranty costs at the time of sale. In general, manufactured products are
warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly
and appropriately maintained. Warranty periods depend on the nature of the product and range from the date of such sale
up to twenty years. The amount of the accrued warranty liability is determined based on historical information such as
past experience, product failure rates or number of units repaired, estimated cost of material and labor and in certain
instances estimated property damage. As of September 29, 2023 and December 31, 2022, the Company had accrued
warranty liabilities of $97 million and $95 million, respectively.
NOTE 15. STOCKHOLDERS' EQUITY AND STOCK-BASED COMPENSATION
Stockholders’ Equity
On July 16, 2013, the Company’s Board of Directors approved a repurchase program (the “Repurchase Program”)
authorizing the repurchase of up to 20 million shares of the Company’s common stock from time to time on the open
market or in privately negotiated transactions. As of September 29, 2023, approximately 20 million shares remained
available for repurchase pursuant to the Repurchase Program.
The following table summarizes the Company’s share activity (shares in millions):
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Preferred stock - shares issued:
Balance, beginning of period — 1.7 1.7 3.4
Conversion of MCPS to common stock — — (1.7) (1.7)
Balance, end of period — 1.7 — 1.7
Common stock - shares issued:
Balance, beginning of period 879.5 868.4 869.3 855.7
Common stock-based compensation
awards 0.7 0.5 2.3 2.2
Conversion of MCPS to common stock — — 8.6 11.0
Balance, end of period 880.2 868.9 880.2 868.9
Table of Contents
20

-- 23 of 49 --

As of April 17, 2023, all outstanding shares of the Company’s 5.00% MCPS Series B converted to common shares at a
rate of 5.0175 common shares per share of preferred stock into an aggregate of 8.6 million shares of the Company’s
common stock, pursuant to the terms of the Certificate of Designation governing the Series B Preferred Stock. On April
15, 2022, all outstanding shares of the Company’s 4.75% MCPS Series A converted to common shares at a rate of 6.6632
common shares per share of preferred stock into an aggregate of 11.0 million shares of the Company’s common stock,
pursuant to the terms of the Certificate of Designation governing the Series A Preferred Stock. For additional information
on the MCPS, refer to Note 19 in the Company’s 2022 Annual Report.
Stock-Based Compensation
For a full description of the Company’s stock-based compensation programs, refer to Note 19 of the Company’s financial
statements as of and for the year ended December 31, 2022 included in the Company’s 2022 Annual Report. As of
September 29, 2023, approximately 41 million shares of the Company’s common stock were reserved for issuance under
the 2007 Omnibus Incentive Plan.
The following information about the Company's stock-based compensation programs includes amounts for both the
Company's and Veralto's employees. In connection with the Separation and in accordance with the employee matters
agreement Danaher and Veralto have entered into, the Company has made certain adjustments to the exercise price and
the number of stock-based compensation awards with the intention of preserving the intrinsic value of the awards
immediately prior to the Separation. Stock-based compensation awards have been converted into awards of the company
that employs the employee post-separation, and Veralto has responsibility for the awards that were converted into Veralto
awards. The adjustment to the Company’s stock-based compensation awards as a result of the Separation is not
expected to have a significant impact to the Company’s stock compensation expense. Stock-based compensation
disclosures reflecting the impact of the Separation will be included in the Company's Annual Report on Form 10-K for the
year ending December 31, 2023.
The following summarizes the components of the Company’s stock-based compensation expense ($ in millions):
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
RSUs/PSUs:
Pretax compensation expense $ 51 $ 52 $ 157 $ 156
Income tax benefit (11) (11) (32) (32)
RSU/PSU expense, net of income taxes 40 41 125 124
Stock options:
Pretax compensation expense 41 37 123 114
Income tax benefit (8) (7) (25) (23)
Stock option expense, net of income taxes 33 30 98 91
Total stock-based compensation:
Pretax compensation expense 92 89 280 270
Income tax benefit (19) (18) (57) (55)
Total stock-based compensation expense, net
of income taxes $ 73 $ 71 $ 223 $ 215
Stock-based compensation has been recognized as a component of selling, general and administrative expenses in the
accompanying Consolidated Condensed Statements of Earnings. As of September 29, 2023, $222 million of total
unrecognized compensation cost related to RSUs/PSUs is expected to be recognized over a weighted average period of
approximately two years. As of September 29, 2023, $269 million of total unrecognized compensation cost related to
stock options is expected to be recognized over a weighted average period of approximately two years. Future
compensation amounts will be adjusted for any changes in estimated forfeitures.
Accumulated Other Comprehensive Income
Accumulated other comprehensive income (loss) refers to certain gains and losses that under U.S. GAAP are included in
comprehensive income (loss) but are excluded from net earnings as these amounts are initially recorded as an adjustment
to stockholders’ equity. Foreign currency translation adjustments generally relate to indefinite investments in non-U.S.
subsidiaries, as well as the impact from the Company’s hedges of its net investment in foreign operations, including the
Company’s cross-currency swap derivatives, net of any income tax impacts.
Table of Contents
21

-- 24 of 49 --

The changes in accumulated other comprehensive income (loss) by component are summarized below ($ in millions).
Foreign
Currency
Translation
Adjustments
Pension and
Postretirement
Plan Benefit
Adjustments
Cash Flow
Hedge
Adjustments
Accumulated
Comprehensive
Income (Loss)
For the Three-Month Period Ended September 29, 2023:
Balance, June 30, 2023 $ (3,323) $ (341) $ 88 $ (3,576)
Other comprehensive income (loss) before reclassifications:
Increase (decrease) (296) — 22 (274)
Income tax impact (7) — — (7)
Other comprehensive income (loss) before reclassifications,
net of income taxes (303) — 22 (281)
Reclassification adjustments:
Increase (decrease) — 1 (a) (102) (b) (101)
Income tax impact — — (1) (1)
Reclassification adjustments, net of income taxes — 1 (103) (102)
Net other comprehensive income (loss), net of income
taxes (303) 1 (81) (383)
Balance, September 29, 2023 $ (3,626) $ (340) $ 7 $ (3,959)
For the Three-Month Period Ended September 30, 2022:
Balance, July 1, 2022 $ (2,324) $ (529) $ 108 $ (2,745)
Other comprehensive income (loss) before reclassifications:
Increase (decrease) (1,008) — 214 (794)
Income tax impact (31) — (51) (82)
Other comprehensive income (loss) before reclassifications,
net of income taxes (1,039) — 163 (876)
Reclassification adjustments:
Increase (decrease) — 9 (a) (240) (b) (231)
Income tax impact — (2) — (2)
Reclassification adjustments, net of income taxes — 7 (240) (233)
Net other comprehensive income (loss), net of income
taxes (1,039) 7 (77) (1,109)
Balance, September 30, 2022 $ (3,363) $ (522) $ 31 $ (3,854)
Table of Contents
22

-- 25 of 49 --

Foreign
Currency
Translation
Adjustments
Pension and
Postretirement
Plan Benefit
Adjustments
Cash Flow
Hedge
Adjustments
Accumulated
Comprehensiv
e Income
(Loss)
For the Nine-Month Period Ended September 29, 2023:
Balance, December 31, 2022 $ (2,644) $ (341) $ 113 $ (2,872)
Other comprehensive income (loss) before reclassifications:
Increase (decrease) (991) — (68) (1,059)
Income tax impact 9 — — 9
Other comprehensive income (loss) before reclassifications,
net of income taxes (982) — (68) (1,050)
Reclassification adjustments:
Increase (decrease) — 1 (a) (37) (b) (36)
Income tax impact — — (1) (1)
Reclassification adjustments, net of income taxes — 1 (38) (37)
Net other comprehensive income (loss), net of income taxes (982) 1 (106) (1,087)
Balance, September 29, 2023 $ (3,626) $ (340) $ 7 $ (3,959)
For the Nine-Month Period Ended September 30, 2022:
Balance, December 31, 2021 $ (539) $ (550) $ 62 $ (1,027)
Other comprehensive income (loss) before reclassifications:
Increase (decrease) (2,729) — 720 (2,009)
Income tax impact (95) — (173) (268)
Other comprehensive income (loss) before reclassifications,
net of income taxes (2,824) — 547 (2,277)
Reclassification adjustments:
Increase (decrease) — 37 (a) (578) (b) (541)
Income tax impact — (9) — (9)
Reclassification adjustments, net of income taxes — 28 (578) (550)
Net other comprehensive income (loss), net of income taxes (2,824) 28 (31) (2,827)
Balance, September 30, 2022 $ (3,363) $ (522) $ 31 $ (3,854)
(a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic benefit cost (refer to Notes 8
and 13 for additional details).
(b) Reflects reclassification to earnings related to cash flow hedges of certain long-term debt (refer to Note 12 for additional details).
Table of Contents
23

-- 26 of 49 --

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is designed to provide
material information relevant to an assessment of Danaher Corporation’s (“Danaher,” the “Company,” “we,” “us” or “our”)
financial condition and results of operations, including an evaluation of the amounts and certainty of cash flows from
operations and from outside sources. The MD&A is designed to focus specifically on material events and uncertainties
known to management that are reasonably likely to cause reported financial information not to be necessarily indicative of
future operating results or of future financial condition. This includes descriptions and amounts of matters that have had a
material impact on reported operations, as well as matters that are reasonably likely based on management’s assessment
to have a material impact on future operations. The Company’s MD&A is divided into five sections:
• Information Relating to Forward-Looking Statements
• Overview
• Results of Operations
• Liquidity and Capital Resources
• Critical Accounting Estimates
You should read this discussion along with the Company’s MD&A and audited financial statements and Notes thereto as
of and for the year ended December 31, 2022, included in the Company’s 2022 Annual Report and the Company’s
Consolidated Condensed Financial Statements and related Notes as of and for the three and nine-month periods ended
September 29, 2023 included in this Quarterly Report on Form 10-Q (“Report”).
INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS
Certain statements included or incorporated by reference in this Report, in other documents we file with or furnish to the
Securities and Exchange Commission, in our press releases, webcasts, conference calls, materials delivered to
shareholders and other communications, are “forward-looking statements” within the meaning of the U.S. federal
securities laws. All statements other than historical factual information are forward-looking statements, including without
limitation statements regarding: projections of revenue, expenses, profit, profit margins, pricing, tax rates, tax provisions,
cash flows, pension and benefit obligations and funding requirements, asset values, our liquidity position or other
projected financial measures; management’s plans and strategies for future operations, including statements relating to
anticipated operating performance, customer demand, cost reductions, restructuring activities, new product and service
developments, competitive strengths or market position, acquisitions and the integration thereof, divestitures, spin-offs,
split-offs, initial public offerings, other securities offerings, or other distributions, strategic opportunities, stock repurchases,
dividends and executive compensation; growth, declines and other trends in markets we sell into; new or modified laws,
regulations and accounting pronouncements; future regulatory approvals and the timing and conditionality thereof;
outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; future foreign currency
exchange rates and fluctuations in those rates; the potential or anticipated direct or indirect impact of COVID-19 and
military conflicts on our business, results of operations and/or financial condition; general economic and capital markets
conditions; the anticipated timing of any of the foregoing; assumptions underlying any of the foregoing; and any other
statements that address events or developments that Danaher intends or believes will or may occur in the future.
Terminology such as “believe,” “anticipate,” “should,” “could,” “intend,” “will,” “plan,” “expect,” “estimate,” “project,” “target,”
“may,” “possible,” “potential,” “forecast” and “positioned” and similar references to future periods are intended to identify
forward-looking statements, although not all forward-looking statements are accompanied by such words.
Forward-looking statements are based on assumptions and assessments made by our management in light of their
experience and perceptions of historical trends, current conditions, expected future developments and other factors.
Forward-looking statements are not guarantees of future performance and actual results may differ materially from the
results, developments and business decisions contemplated by our forward-looking statements. Accordingly, you should
not place undue reliance on any such forward-looking statements. Important factors that in some cases have affected us
in the past and that in the future could cause actual results to differ materially from those envisaged in the forward-looking
statements include the following:
Business and Strategic Risks
• The COVID-19 pandemic, and declines in demand as the pandemic has evolved to endemic status, have
adversely impacted and could in the future continue to adversely impact elements of our business and financial
statements. Other conditions in the global economy, the particular markets we serve and the financial markets
can also adversely affect our business and financial statements.
Table of Contents
24

-- 27 of 49 --

• We face intense competition and if we are unable to compete effectively, we may experience decreased demand
and decreased market share. Even if we compete effectively, we may be required to reduce the prices we
charge.
• Our growth depends on the timely development and commercialization, and customer acceptance, of new and
enhanced products and services based on technological innovation. Our growth can also suffer if the markets
into which we sell our products and services decline, do not grow as anticipated or experience cyclicality.
• The healthcare industry and related industries that we serve are undergoing significant changes in an effort to
reduce (and increase the predictability of) costs, which can adversely affect our business and financial
statements.
• Non-U.S. economic, political, legal, compliance, social and business factors (including military conflicts) can
negatively affect our business and financial statements.
• Collaborative partners and other third-parties we rely on for development, supply and/or marketing of certain
products, potential products and technologies could fail to perform sufficiently.
Acquisitions, Divestitures and Investment Risks
• Any inability to consummate acquisitions at our historical rate and appropriate prices, and to make appropriate
investments that support our long-term strategy, could negatively impact our business.
• Our acquisition of businesses, investments, joint ventures and other strategic relationships could also negatively
impact our business and financial statements and our indemnification rights may not fully protect us from liabilities
related thereto. In addition, acquisitions (including Danaher’s pending acquisition of Abcam plc) can be difficult to
complete on the anticipated timetable or at all for a number of reasons, including the uncertainty of regulatory
approvals and the timing or conditionality thereof, and the parties' ability to satisfy the acquisition agreement
conditions, including as applicable the receipt of shareholder approval.
• Divestitures or other dispositions (including the Veralto Separation) could negatively impact our business, and
contingent liabilities from Veralto or from other businesses that we or our predecessors have disposed or will
dispose in the future could adversely affect our business and financial statements. For example, we could incur
significant liability if the Veralto Separation or any of the other split-off or spin-off transactions we have previously
consummated are determined to be a taxable transaction or otherwise pursuant to our indemnification obligations
with respect to such transactions.
Operational Risks
• Significant disruptions in, or breaches in security of, our information technology (“IT”) systems or data; data
privacy violations; other losses or disruptions to facilities, supply chains, distribution systems or IT systems due to
catastrophe; and labor disputes can all adversely affect our business and financial statements.
• Defects and unanticipated use or inadequate disclosure with respect to our products or services, or allegations
thereof, can adversely affect our business and financial statements.
• Our financial results are subject to fluctuations in the cost and availability of the supplies (including commodities)
we use in, and the labor we need for, our operations. Over the past year, we have at times experienced to
varying degrees supply chain disruptions including in some cases shortages of supply, cost inflation and shipping
delays, labor availability constraints and labor cost increases.
• Climate change, legal or regulatory measures to address climate change and any inability to address stakeholder
expectations with respect to climate change, may negatively affect us.
• Our success depends on our ability to recruit, retain and motivate talented employees representing diverse
backgrounds, experiences and skill sets.
• Our restructuring actions can have long-term adverse effects on our business and financial statements.
Intellectual Property Risks
• Any inability to adequately protect or avoid third-party infringement of our intellectual property, and third-party
claims we are infringing intellectual property rights, can adversely affect our business and financial statements.
Table of Contents
25

-- 28 of 49 --

• The U.S. government has certain rights with respect to incremental production capacity attributable to, and/or the
intellectual property we have developed using, government financing. In addition, in times of national emergency
the U.S. government has authority to control our allocation of manufacturing capacity.
Financial and Tax Risks
• Our outstanding debt has increased significantly as a result of acquisitions, and we may incur additional debt.
Such indebtedness may limit our operations and use of cash flow and negatively impact our credit ratings; and
failure to comply with our indebtedness-related covenants could adversely affect our business and financial
statements.
• Our business and financial statements can be adversely affected by foreign currency exchange rates, changes in
our tax rates (including as a result of changes in tax laws) or income tax liabilities/assessments, the outcome of
tax audits, financial market risks related to our defined benefit pension plans, health care costs and recognition of
impairment charges for our goodwill or other intangible assets.
Legal, Regulatory, Compliance and Reputational Risks
• Significant developments or changes in national laws or policies to protect or promote domestic interests and/or
address foreign competition can have an adverse effect on our business and financial statements.
• Our businesses are subject to extensive regulation (including those applicable to the healthcare industry). Failure
to comply with those regulations (including by our employees, agents or business partners) or significant
developments or changes in laws or policies can adversely affect our business and financial statements.
• With respect to the regulated medical devices we offer, product introductions or modifications may require
regulatory clearance or authorizations and we could be required to recall or cease marketing such products; off-
label marketing could result in penalties; and clinical trials may have results that are unexpected or are perceived
unfavorably by the market, all of which could adversely affect our business and financial statements.
• We are subject to or otherwise responsible for a variety of litigation and other legal and regulatory proceedings in
the course of our business that can adversely affect our business and financial statements.
• Our operations, products and services also expose us to the risk of environmental, health and safety liabilities,
costs and violations that could adversely affect our business and financial statements.
• Our By-law exclusive forum provisions could limit our stockholders’ ability to choose their preferred judicial forum
for disputes.
See “Part I—Item 1A. Risk Factors” of the Company’s 2022 Annual Report for further discussion regarding reasons that
actual results may differ materially from the results, developments and business decisions contemplated by our forward-
looking statements. Forward-looking statements speak only as of the date of the report, document, press release,
webcast, call, materials or other communication in which they are made. Except to the extent required by applicable law,
we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new
information, future events and developments or otherwise.
OVERVIEW
General
As a result of the Company’s geographic and industry diversity, the Company faces a variety of opportunities and
challenges, including rapid technological development in most of the Company’s served markets, the expansion and
evolution of opportunities in high-growth markets, trends and costs associated with a global labor force, consolidation of
the Company’s competitors and increasing regulation. The Company operates in a highly competitive business
environment in most markets, and the Company’s long-term growth and profitability will depend in particular on its ability
to expand its business in high-growth geographies and high-growth market segments, identify, consummate and integrate
appropriate acquisitions and identify and consummate appropriate investments and strategic partnerships, develop
innovative and differentiated new products and services with higher gross profit margins, expand and improve the
effectiveness of the Company’s sales force, continue to reduce costs and improve operating efficiency and quality and
effectively address the demands of an increasingly regulated global environment. The Company is making significant
investments, organically and through acquisitions and investments, to address the rapid pace of technological change in
its served markets and to globalize its manufacturing, research and development and customer-facing resources
(particularly in high-growth markets) to be responsive to the Company’s customers throughout the world and improve the
efficiency of the Company’s operations.
Table of Contents
26

-- 29 of 49 --

Business Performance and Outlook
During the third quarter of 2023, the Company’s overall revenues decreased 10.5% compared to the comparable period of
2022. Core sales decreased 11.5% in the third quarter of 2023 compared to the comparable prior year period due
primarily to the decline of demand for COVID-19-related products, and to a lesser extent declines in demand for other
products and services. The impact of currency translation increased reported sales 0.5% in the third quarter of 2023
compared to the comparable prior year period. For the nine-month period ended September 29, 2023, overall revenues
decreased 8.0% and core sales decreased 7.5% compared to the comparable prior year period due primarily to the
decline of demand for COVID-19-related products, partially offset by increases in demand for other products and services.
The impact of currency translation decreased reported sales by 1.0% in the nine-month period compared to the
comparable prior year period. For the definition of “core sales” refer to “—Results of Operations” below.
Geographically, the Company’s sales in the three-month period ended September 29, 2023 in developed markets
decreased year-over-year by 11% driven primarily by decreased sales in North America, and to a lesser extent in Western
Europe. For the same period, core sales in developed markets declined at a low-double digit rate, with the declines
primarily attributable to the same geographic regions. The decline in core sales was primarily driven by reduced demand
for products and services related to diagnostic testing associated with COVID-19 in North America and Western Europe
and a reduction in year-over-year demand in the Biotechnology segment. For the same period, sales in high-growth
markets decreased year-over-year by 9% due primarily to mid-teens core revenue declines in China, led by declines in the
Biotechnology segment due to deterioration in the funding environment and lower underlying activity levels. For the same
period, core sales in high-growth markets declined at a high-single digit rate, with the declines primarily attributable to the
same geographic factor. High-growth markets represented approximately 31% of the Company’s total sales in the third
quarter of 2023. For additional information regarding the Company’s sales by geographical region during the three and
nine-month periods ended September 29, 2023 and September 30, 2022, refer to Note 5 to the accompanying
Consolidated Condensed Financial Statements.
The Company’s net earnings for the three and nine-month periods ended September 29, 2023 totaled approximately $1.1
billion and $3.7 billion, respectively, compared to approximately $1.6 billion and $5.0 billion, respectively, for the three and
nine-month periods ended September 30, 2022. Net earnings attributable to common stockholders for the three and nine-
month periods ended September 29, 2023 totaled approximately $1.1 billion or $1.51 per diluted common share and
approximately $3.7 billion or $4.94 per diluted common share, respectively, compared to approximately $1.6 billion or
$2.10 per diluted common share and approximately $4.9 billion or $6.67 per diluted common share, respectively, for the
three and nine-month periods ended September 30, 2022. Decreased core sales in the 2023 period drove the year-over-
year decrease in net earnings and diluted net earnings per common share for both the three and nine-month periods
ended September 29, 2023.
In an effort to moderate inflationary pressure, the U.S. Federal Reserve and other central banks around the world have
raised interest rates, which has tightened the global credit environment. While the Company’s interest costs and liquidity
were not significantly impacted during the three and nine-month periods ended September 29, 2023 by this credit
tightening due to the significant cash flow generated from the Company’s operations and the predominantly fixed-interest
rates of the Company’s outstanding borrowings, the credit tightening has adversely impacted demand from certain of the
Company’s customers, including emerging biotechnology companies.
In response to the attack in Israel and the subsequent hostilities, the Company is continuing to monitor the social, political
and economic environment in Israel and in the region for any impact on its operations and value chain. As of December
31, 2022, the Company’s net investment in property, plant and equipment in Israel was less than $1 million. For the year
ended December 31, 2022, sales to Israel were less than $100 million. While we are monitoring the conflict, as of the
date of this report we do not expect the conflict will have a material impact on our business.
The COVID-19 Pandemic
Overall conditions related to COVID-19 have improved in 2023 compared to 2022 (including the announcement on April
10, 2023 that the U.S. public health emergency related to COVID-19 ended). The Company has deployed our
capabilities, expertise and scale to address the critical health needs related to COVID-19, including making available
diagnostic tests for the rapid detection of COVID-19 and support for production of vaccines and therapies for COVID-19.
Demand for the Company’s products that support COVID-19 related vaccines and therapeutics (including related to
research and development that seeks to prevent or mitigate similar, future pandemics) decreased in both the three and
nine-month periods ended September 29, 2023 versus the comparable periods of 2022. The Company expects overall
demand for these products to continue to decrease in the fourth quarter of 2023 compared to the fourth quarter of 2022 in
response to COVID-19 evolving to an endemic status. Additionally, demand for the Company’s products that support
COVID-19 testing is expected to continue to fluctuate, corresponding to fluctuations in COVID-19 cases in particular
geographies. Demand for the Company’s COVID-19 related testing products decreased in the three and nine-month
Table of Contents
27

-- 30 of 49 --

periods ended September 29, 2023 versus the comparable periods of 2022. In response to COVID-19 evolving to an
endemic status, the Company continues to review and adjust its cost structure.
For additional information on the risks of COVID-19 to the Company’s operations, refer to the “Part I—Item 1A. Risk
Factors” section of the Company’s 2022 Annual Report and “Information Relating to Forward-Looking Statements” in Part
I, Item 2 of this Report.
Pending Acquisition
On August 28, 2023, the Company entered into a definitive agreement to acquire all of the outstanding shares of Abcam
plc (“Abcam”) for a cash purchase price of approximately $5.7 billion, including assumed indebtedness and net of
acquired cash (the “Abcam Acquisition”). Abcam is a leading global supplier of protein consumables, including highly
validated antibodies, reagents, biomarkers and assays to address targets in biological pathways that are critical for
advancing drug discovery, life sciences research and diagnostics. Abcam generated revenues of £362 million in 2022.
The Company expects to include the Abcam business within its Life Sciences segment. The transaction is subject to
customary closing conditions, including receipt of applicable regulatory approvals and Abcam shareholder approval.
The Company expects to finance the Abcam Acquisition using cash on hand and/or the proceeds from the issuance of
commercial paper.
Separation of the Environmental & Applied Solutions Business
Effective as of September 30, 2023, the Company completed the separation of its former Environmental & Applied
Solutions business to Veralto Corporation (the “Separation”). As the disposition occurred during the fourth quarter of
2023, the Company will classify Veralto as a discontinued operation in its historical financial statements beginning with the
fourth quarter of 2023. For additional information, refer to Note 3 to the accompanying Consolidated Condensed Financial
Statements
Currency Exchange Rates
Currency exchange rates increased reported sales by approximately 0.5% for the three-month period and decreased
reported sales by approximately 1.0% for the nine-month period ended September 29, 2023 compared to the comparable
periods of 2022, primarily due to the exchange rates of the U.S. dollar compared to the euro and most other major
currencies in 2023. If the currency exchange rates in effect as of September 29, 2023 were to prevail throughout the
remainder of 2023, currency exchange rates would be essentially flat relative to the fourth quarter of 2022 and full year
2023 sales would decrease by approximately 0.5% on a year-over-year basis. Strengthening of the U.S. dollar against
other major currencies compared to the exchange rates in effect as of September 29, 2023 would adversely impact the
Company’s sales on an overall basis, and any weakening of the U.S. dollar against other major currencies compared to
the exchange rates in effect as of September 29, 2023 would positively impact the Company’s sales and results of
operations for the remainder of the year.
RESULTS OF OPERATIONS
Non-GAAP Measures
In this report, references to the non-GAAP measures of core sales (also referred to as core revenues or sales/revenues
from existing businesses) refer to sales calculated according to U.S. GAAP, but excluding:
• sales from acquired businesses (as defined below, as applicable); and
• the impact of currency translation.
References to sales or operating profit attributable to acquisitions or acquired businesses refer to sales or operating profit,
as applicable, from acquired businesses recorded prior to the first anniversary of the acquisition less any sales and
operating profit, during the applicable period, attributable to divested product lines not considered discontinued operations.
The portion of revenue attributable to currency translation is calculated as the difference between:
• the period-to-period change in revenue (excluding sales from acquired businesses (as defined above, as
applicable)); and
• the period-to-period change in revenue (excluding sales from acquired businesses (as defined above, as
applicable)) after applying current period foreign exchange rates to the prior year period.
Core sales growth should be considered in addition to, and not as a replacement for or superior to, sales, and may not be
comparable to similarly titled measures reported by other companies. Management believes that reporting this non-GAAP
financial measure provides useful information to investors by helping identify underlying growth trends in Danaher’s
Table of Contents
28

-- 31 of 49 --

business and facilitating comparisons of Danaher’s revenue performance with its performance in prior and future periods
and to Danaher’s peers. Management also uses this non-GAAP financial measure to measure the Company’s operating
and financial performance and uses core sales growth as one of the performance measures in the Company’s executive
short-term cash incentive compensation program. The Company excludes the effect of currency translation from this
measure because currency translation is not under management’s control, is subject to volatility and can obscure
underlying business trends, and excludes the effect of acquisitions and divestiture-related items because the nature, size,
timing and number of acquisitions and divestitures can vary dramatically from period-to-period and between the Company
and its peers and can also obscure underlying business trends and make comparisons of long-term performance difficult.
Throughout this discussion, references to sales growth or decline refer to the impact of both price and unit sales and
references to productivity improvements generally refer to improved cost-efficiencies resulting from the ongoing
application of the Danaher Business System.
Sales (Decline) Growth and Core Sales (Decline) Growth
% Change Three-
Month Period Ended
September 29, 2023
vs. Comparable 2022
Period
% Change Nine-
Month Period Ended
September 29, 2023
vs. Comparable 2022
Period
Total sales (decline) growth (GAAP) (10.5) % (8.0)%
Impact of:
Acquisitions/divestitures (0.5) % (0.5)%
Currency exchange rates (0.5) % 1.0 %
Core sales (decline) growth (non-GAAP) (11.5) % (7.5)%
2023 Sales Compared to 2022
Total sales decreased 10.5% and 8.0% during the three and nine-month periods ended September 29, 2023 compared to
the three and nine-month periods ended September 30, 2022, respectively, primarily as a result of the decrease in core
sales due to the factors discussed below by segment. The impact of currency translation increased reported sales 0.5%
on a year-over-year basis during the three-month period ended September 29, 2023, primarily due to the year-over-year
impact of the weakening of the U.S. dollar against most other major currencies for the three-month period, and decreased
reported sales 1.0% on a year-over-year basis during the nine-month period ended September 29, 2023, primarily due to
the year-over-year impact of the strengthening of the U.S. dollar against the euro and most other major currencies for the
nine-month period. Price increases contributed 3.0% to sales growth on a year-over-year basis during both the three and
nine-month periods ended September 29, 2023 and are reflected as a component of core sales decline above.
Operating Profit Performance
Operating profit margins decreased 540 basis points from 26.3% during the three-month period ended September 30,
2022 to 20.9% for the three-month period ended September 29, 2023. The following factors unfavorably impacted year-
over-year operating profit margin:
• Lower third quarter 2023 core sales, the impact of product mix and reduced leverage in the Company’s
operational and administrative cost structure - 470 basis points
• Third quarter 2023 costs incurred related to preparation for the separation of the Company's Environmental &
Applied Solutions business - 55 basis points
• Third quarter 2023 impairment charges related to a trade name in the Environmental & Applied Solutions
segment - 10 basis points
• The incremental dilutive effect in 2023 of acquired businesses - 5 basis points
Operating profit margins decreased 570 basis points from 27.7% during the nine-month period ended September 30, 2022
to 22.0% for the nine-month period end September 29, 2023.
Year-to-date 2023 vs. year-to-date 2022 operating profit margin comparisons were unfavorably impacted by:
• Lower 2023 core sales, the impact of product mix, inventory write-offs and reduced leverage in the Company’s
operational and administrative cost structure - 510 basis points
• First nine months of 2023 costs incurred related to preparation for the separation of the Company's
Environmental & Applied Solutions business - 45 basis points
Table of Contents
29

-- 32 of 49 --

• Second quarter 2023 impairment charges related to technology and other assets in the Biotechnology segment
and customer relationships in the Environmental & Applied Solutions segments and a third quarter 2023
impairment charge related to a trade name in the Environmental & Applied Solutions segment, net of a second
quarter 2022 impairment charge related to technology and customer relationships in the Environmental & Applied
Solutions segment - 20 basis points
• The incremental dilutive effect in 2023 of acquired businesses - 10 basis points
Year-to-date 2023 vs. year-to-date 2022 operating profit margin comparisons were favorably impacted by:
• First nine months of 2022 impairments of accounts receivable and inventory as well as accruals for contractual
obligations in Russia - 15 basis points
Business Segments
Sales by business segment for each of the periods indicated were as follows ($ in millions):
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Biotechnology $ 1,664 $ 2,053 $ 5,413 $ 6,535
Life Sciences 1,706 1,723 5,211 5,090
Diagnostics 2,254 2,679 6,861 7,884
Environmental & Applied Solutions 1,249 1,208 3,712 3,593
Total $ 6,873 $ 7,663 $ 21,197 $ 23,102
For information regarding the Company’s sales by geographical region, refer to Note 5 to the accompanying Consolidated
Condensed Financial Statements.
BIOTECHNOLOGY
The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range
of tools, consumables and services that are primarily used by customers to advance and accelerate the research,
development, manufacture and delivery of biological medicines. The biotherapeutics that the Company’s solutions
support range from replacement therapies such as insulin, vaccines, recombinant proteins and other biologic drugs, to
novel cell, gene, mRNA and other nucleic acid therapies.
Biotechnology Selected Financial Data
Three-Month Period Ended Nine-Month Period Ended
($ in millions) September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Sales $ 1,664 $ 2,053 $ 5,413 $ 6,535
Operating profit 417 691 1,493 2,315
Depreciation 40 40 119 127
Amortization of intangible assets 214 197 649 616
Operating profit as a % of sales 25.1 % 33.7 % 27.6 % 35.4 %
Depreciation as a % of sales 2.4 % 1.9 % 2.2 % 1.9 %
Amortization as a % of sales 12.9 % 9.6 % 12.0 % 9.4 %
Sales (Decline) Growth and Core Sales (Decline) Growth
% Change Three-
Month Period Ended
September 29, 2023
vs. Comparable 2022
Period
% Change Nine-
Month Period Ended
September 29, 2023
vs. Comparable 2022
Period
Total sales (decline) growth (GAAP) (19.0) % (17.0)%
Impact of:
Acquisitions/divestitures (0.5) % — %
Currency exchange rates (1.5) % 0.5 %
Core sales (decline) growth (non-GAAP) (21.0) % (16.5)%
Table of Contents
30

-- 33 of 49 --

Price increases in the segment contributed 5.0% and 4.0% to sales growth on a year-over-year basis during the three and
nine-month periods ended September 29, 2023, respectively, and are reflected as a component of core sales decline
above.
Total segment sales decreased 19.0% and 17.0% during the three and nine-month periods, respectively, led by decreased
core sales in both periods resulting from the factors discussed below, particularly lower year-over-year sales related to
COVID-19 and lower core sales in the bioprocessing business. The impact of acquisitions and changes in currency
exchange rates increased sales in the three-month period, while the impact of changes in currency exchange rates
decreased sales in the nine-month period. In both periods, total segment core sales decreased in North America, China
and Western Europe. Core sales in the bioprocessing business decreased year-over-year during both the three and nine-
month periods primarily due to lower end-customer demand for COVID-19 related therapeutics and vaccines and the
reduction of customer inventory levels. Bioprocessing business core sales decreased more than 20% in the three-month
period and decreased approximately 45% in China in the same period. Core sales in the discovery and medical business
decreased year-over-year during both the three and nine-month periods due to lower demand for lab filtration, medical
and diagnostics and genomics product lines, partially offset by increased demand for protein research products.
Additionally, the Company believes that the tightening credit environment also contributed to a reduction in year-over-year
demand from emerging biotechnology companies during both periods as these customers continued to preserve capital.
The Company expects the impact of reduced demand and reduction of customer inventory levels to continue at least
through the remainder of the year.
Operating Profit Performance
Operating profit margins decreased 860 basis points during the three-month period ended September 29, 2023 as
compared to the comparable period of 2022.
Third quarter 2023 vs. third quarter 2022 operating profit margin comparisons were unfavorably impacted by:
• Lower third quarter 2023 core sales, the impact of product mix, higher amortization expense and reduced
leverage in the Company’s operational and administrative cost structure - 865 basis points
Third quarter 2023 vs. third quarter 2022 operating profit margin comparisons were favorably impacted by:
• Incremental accretive effect in 2023 of acquired businesses - 5 basis points
Operating profit margins decreased 780 basis points during the nine-month period ended September 29, 2023 as
compared to the comparable period of 2022.
Year-to-date 2023 vs. year-to-date 2022 operating profit margin comparisons were unfavorably impacted by:
• Lower 2023 core sales, the impact of product mix, inventory write-offs, higher amortization expense and reduced
leverage in the Company’s operational and administrative cost structure - 710 basis points
• Second quarter 2023 impairment charges related to technology and other assets - 80 basis points
• Incremental dilutive effect in 2023 of acquired businesses - 10 basis points
Year-to-date 2023 vs. year-to-date 2022 operating profit margin comparisons were favorably impacted by:
• First nine months of 2022 impairments of accounts receivable and inventory in Russia - 20 basis points
Amortization of intangible assets as a percentage of sales increased during both the three and nine-month periods ended
September 29, 2023 as compared with 2022, primarily as a result of the decrease in sales and to a lesser extent
increased year-over year amortization from the change of a trade name from indefinite-lived to definite-lived.
LIFE SCIENCES
The Life Sciences segment offers a broad range of instruments and consumables that are primarily used by customers to
study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to
understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene
editing technologies. Additionally, the segment provides products and consumables used to filter and remove
contaminants from a variety of liquids and gases in many end-market applications.
Table of Contents
31

-- 34 of 49 --

Life Sciences Selected Financial Data
Three-Month Period Ended Nine-Month Period Ended
($ in millions) September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Sales $ 1,706 $ 1,723 $ 5,211 $ 5,090
Operating profit 313 354 974 1,022
Depreciation 31 29 92 84
Amortization of intangible assets 104 103 313 315
Operating profit as a % of sales 18.3 % 20.5 % 18.7 % 20.1 %
Depreciation as a % of sales 1.8 % 1.7 % 1.8 % 1.7 %
Amortization as a % of sales 6.1 % 6.0 % 6.0 % 6.2 %
Sales Growth and Core Sales Growth
% Change Three-
Month Period Ended
September 29, 2023
vs. Comparable 2022
Period
% Change Nine-
Month Period Ended
September 29, 2023
vs. Comparable 2022
Period
Total sales growth (GAAP) (1.0) % 2.5 %
Impact of:
Acquisitions/divestitures (1.0) % (1.0)%
Currency exchange rates (0.5) % 1.0 %
Core sales growth (non-GAAP) (2.5) % 2.5 %
Price increases in the segment contributed 4.0% to sales growth on a year-over-year basis during both the three and nine-
month periods ended September 29, 2023 and are reflected as a component of core sales growth.
Total segment sales decreased 1.0% during the three-month period and increased 2.5% during the nine-month period.
Total segment core sales decreased year-over-year in the three-month period as a result of the decline in COVID-19
related sales and weakness at pharma and biopharma customers, partially offset by the impact of acquisitions and
currency exchange rates. Total segment core sales increased year-over-year in the nine-month period as a result of
increased demand in the life science research, academic and applied end-markets and the impact of acquisitions, partially
offset by the decline in COVID-19 related sales, weakness at pharma and biopharma customers and the impact of
currency exchange rates. Geographically, overall segment core sales decreased in the three-month period in North
America and to a lesser extent, China, partially offset by Western Europe. Core sales increased in the nine-month period
in Western Europe and China, partially offset by declines in North America. In the three-month period, the decrease in
core sales was driven by the flow cytometry, genomics, lab automation, centrifugation, particle counting and
characterization business due to reduced demand across most product lines and in the genomics medicine business from
reduced demand in next generation sequencing and basic research. These declines were partially offset by increased
core sales in the industrial filtration business. In the nine-month period, the increase in core sales was driven by the
industrial filtration business, the mass spectrometry business and the microscopy business. These increases were
partially offset by lower core sales in the genomics medicine business as a result of reduced demand for COVID-19
related products and to a lesser extent from reduced demand in next generation sequencing and basic research, net of
increased demand for plasmids, proteins and gene writing and editing solutions.
Operating Profit Performance
Operating profit margins decreased 220 basis points during the three-month period ended September 29, 2023 as
compared to the comparable period of 2022. The following factors unfavorably impacted year-over-year operating profit
margin:
• Lower third quarter 2023 core sales, the impact of product mix and reduced leverage in the Company’s
operational and administrative cost structure - 195 basis points
• The incremental dilutive effect in 2023 of acquired businesses - 25 basis points
Operating profit margins decreased 140 basis points during the nine-month period ended September 29, 2023 as
compared to the comparable period of 2022.
Table of Contents
32

-- 35 of 49 --

Year-to-date 2023 vs. year-to-date 2022 operating profit margin comparisons were unfavorably impacted by:
• The impact of product mix and reduced leverage in the Company’s operational and administrative cost structure,
net of higher 2023 core sales - 155 basis points
• The incremental dilutive effect in 2023 of acquired businesses - 35 basis points
Year-to-date 2023 vs. year-to-date 2022 operating profit margin comparisons were favorably impacted by:
• First nine months of 2022 impairments of accounts receivable and inventory as well as accruals for contractual
obligations in Russia - 50 basis points
DIAGNOSTICS
The Diagnostics segment offers clinical instruments, reagents, consumables, software and services that hospitals,
physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment
decisions.
Diagnostics Selected Financial Data
Three-Month Period Ended Nine-Month Period Ended
($ in millions) September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Sales $ 2,254 $ 2,679 $ 6,861 $ 7,884
Operating profit 539 761 1,640 2,447
Depreciation 93 98 282 290
Amortization of intangible assets 49 50 149 151
Operating profit as a % of sales 23.9 % 28.4 % 23.9 % 31.0 %
Depreciation as a % of sales 4.1 % 3.7 % 4.1 % 3.7 %
Amortization as a % of sales 2.2 % 1.9 % 2.2 % 1.9 %
Sales (Decline) Growth and Core Sales (Decline) Growth
% Change Three-
Month Period Ended
September 29, 2023
vs. Comparable 2022
Period
% Change Nine-
Month Period Ended
September 29, 2023
vs. Comparable 2022
Period
Total sales (decline) growth (GAAP) (16.0) % (13.0) %
Impact of:
Currency exchange rates 0.5 % 1.5 %
Core sales (decline) growth (non-GAAP) (15.5) % (11.5) %
Price increases in the segment contributed 1.0% to sales growth on a year-over-year basis during both the three and nine-
month periods ended September 29, 2023 and are reflected as a component of core sales decline.
Total segment sales decreased 16.0% and 13.0% during the three and nine-month periods, respectively, primarily as a
result of decreased core sales resulting from the factors discussed below, particularly lower year-over-year core sales of
molecular diagnostics tests for COVID-19, and to a lesser extent due to the impact of changes in currency exchange
rates. In both periods, overall segment core sales declines were driven primarily by year-over-year declines in North
America, and to a lesser extent in Western Europe. During both the three and nine-month periods, core sales in the
molecular diagnostics business decreased on a year-over-year basis as the business experienced declines in sales of
diagnostic test solutions for COVID-19, partially offset by increased sales of non-respiratory disease tests, which
increased over 20% in the three-month period. Core sales in the segment’s clinical diagnostics businesses grew on a
year-over-year basis in both the three and nine-month periods, led by the clinical lab business in North America, and to a
lesser extent, the acute care and pathology businesses.
Operating Profit Performance
Operating profit margins decreased 450 basis points during the three-month period ended September 29, 2023 as
compared to the comparable period of 2022. The following factors unfavorably impacted year-over-year operating profit
margin:
• Lower third quarter 2023 core sales, the impact of product mix and reduced leverage in the Company’s
operational and administrative cost structure - 445 basis points
Table of Contents
33

-- 36 of 49 --

• The incremental dilutive effect in 2023 of acquired businesses - 5 basis points
Operating profit margins decreased 710 basis points during the nine-month period ended September 29, 2023 as
compared to the comparable period of 2022.
Year-to-date 2023 vs. year-to-date 2022 operating profit margin comparisons were unfavorably impacted by:
• Lower 2023 core sales, the impact of product mix and reduced leverage in the Company’s operational and
administrative cost structure - 710 basis points
• The incremental dilutive effect in 2023 of acquired businesses - 5 basis points
Year-to-date 2023 vs. year-to-date 2022 operating profit margin comparisons were favorably impacted by:
• First nine months of 2022 impairments of accounts receivable and inventory as well as accruals for contractual
obligations in Russia - 5 basis points
Depreciation and amortization increased as a percentage of sales during both the three and nine-month periods ended
September 29, 2023, primarily as a result of the decrease in sales.
ENVIRONMENTAL & APPLIED SOLUTIONS
The businesses that comprised Danaher’s Environmental & Applied Solutions segment prior to the Separation are a
provider of essential technology solutions, unified under a common purpose of Safeguarding the World’s Most Vital
ResourcesTM, to support customers to address large global challenges including environmental resource sustainability,
water scarcity, management of severe weather events, food and pharmaceutical security and the impact of an aging
workforce.
The Company’s water quality business provides proprietary precision instrumentation and advanced water treatment
technologies to help measure, analyze and treat the world’s water in residential, commercial, municipal, industrial,
research and natural resource applications. In addition to instrumentation, the water quality businesses also provide
chemical reagents, services and digital solutions. The Company’s product identification business provides marking and
coding, and packaging and color instrumentation and related consumables for brand owners and consumer packaged
goods companies that enable speed to market as well as traceability and quality control of their products. The product
identification business’s solutions help customers across consumer, pharmaceutical and industrial sectors to bring
products to market, mark packaging in compliance with industry and regulatory standards and convey the safety of
products to their customers.
Effective as of September 30, 2023, the first day of the Company’s fourth quarter of 2023, the Company completed the
separation of its former Environmental & Applied Solutions business to Veralto.
Environmental & Applied Solutions Selected Financial Data
Three-Month Period Ended Nine-Month Period Ended
($ in millions) September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Sales $ 1,249 $ 1,208 $ 3,712 $ 3,593
Operating profit 286 286 887 829
Depreciation 9 10 29 31
Amortization of intangible assets 12 11 36 38
Operating profit as a % of sales 22.9 % 23.7 % 23.9 % 23.1 %
Depreciation as a % of sales 0.7 % 0.8 % 0.8 % 0.9 %
Amortization as a % of sales 1.0 % 0.9 % 1.0 % 1.1 %
Table of Contents
34

-- 37 of 49 --

Sales Growth and Core Sales Growth
% Change Three-
Month Period Ended
September 29, 2023
vs. Comparable 2022
Period
% Change Nine-
Month Period Ended
September 29, 2023
vs. Comparable 2022
Period
Total sales growth (GAAP) 3.5 % 3.5 %
Impact of:
Acquisitions/divestitures (0.5) % (0.5) %
Currency exchange rates (2.0) % — %
Core sales growth (non-GAAP) 1.0 % 3.0 %
Price increases in the segment contributed 3.5% and 4.5% to sales growth on a year-over-year basis during the three and
nine-month periods ended September 29, 2023, respectively, and are reflected as a component of core sales growth.
Total segment sales increased 3.5% during both the three and nine-month periods. In the three-month period, the
increase was a result of core sales growth driven by the factors discussed below, changes in currency exchange rates and
acquisitions. In the nine-month period, the increase was primarily as a result of core sales growth driven by the factors
discussed below, and to a lesser extent acquisitions.
Core sales in the segment’s water quality businesses increased at a low-single and mid-single digit rate during the three
and nine-month periods ended September 29, 2023, respectively, compared to the comparable periods of 2022. The
increase in core sales in the three-month period was driven primarily by the chemical treatment solutions and ultraviolet
water disinfection product lines. The increase in core sales in the nine-month period was driven primarily by the analytical
instrumentation product line, and to a lesser extent by the chemical treatment solutions product line. Geographically, the
increase in core sales in both periods was led primarily by North America, and to a lesser extent by Western Europe,
partially offset by China. Core sales in the business’ chemical treatment solutions product line increased year-over-year
during both the three and nine-month periods as a result of increased core sales across most major end-markets. Core
sales in the business’ ultraviolet water disinfection product line increased year-over-year during the three-month period,
driven by demand in the municipal and residential end-markets. Year-over-year core sales in the analytical
instrumentation product line increased in the nine-month period driven by the industrial and municipal end-markets in the
developed markets, partially offset by lower demand in China.
Core sales in the segment’s product identification businesses decreased at a low-single digit rate during both the three
and nine-month periods ended September 29, 2023 compared to the comparable periods of 2022. The decrease in core
sales was primarily driven by the packaging and color solutions business in the three-month period and both the marking
and coding business and the packaging and color solutions business in the nine-month period. Geographically, the
decrease in core sales in the three-month period was led primarily by China and North America, partially offset by Latin
America, and in the nine-month period was led by North America and China, partially offset by Latin America and Western
Europe. For the packaging and color solutions business, core sales decreased in both the three and nine-month periods
primarily driven by reduced capital spending across the consumer packaged goods and industrial end-markets. Core
sales in the marking and coding business was essentially flat in the three-month period and decreased during the nine-
month period driven by lower demand in the consumer packaged goods and industrial end-markets.
Operating Profit Performance
Operating profit margins decreased 80 basis points during the three-month period ended September 29, 2023 as
compared to the comparable period of 2022.
Third quarter 2023 vs. third quarter 2022 operating profit margin comparisons were unfavorably impacted by:
• Third quarter 2023 impairment charges related to a trade name - 50 basis points
• The reduced leverage in the Company’s operational and administrative cost structure, net of higher third quarter
2023 core sales and the impact of product mix - 40 basis points
Third quarter 2023 vs. third quarter 2022 operating profit margin comparisons were favorably impacted by:
• The incremental net accretive effect in 2023 of acquired businesses - 10 basis points
Operating profit margins increased 80 basis points during the nine-month period ended September 29, 2023 as compared
to the comparable period of 2022.
Table of Contents
35

-- 38 of 49 --

Year-to-date 2023 vs. year-to-date 2022 operating profit margin comparisons were favorably impacted by:
• Higher 2023 core sales, net of the impact of product mix - 75 basis points
• The incremental net accretive effect in 2023 of acquired businesses - 10 basis points
Year-to-date 2023 vs. year-to-date 2022 operating profit margin comparisons were unfavorably impacted by:
• Second quarter 2023 impairment charges related to customer relationships and third quarter 2023 impairment
charges related to a trade name, net of a second quarter 2022 impairment charge related to technology and
customer relationships - 5 basis points
COST OF SALES AND GROSS PROFIT
Three-Month Period Ended Nine-Month Period Ended
($ in millions) September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Sales $ 6,873 $ 7,663 $ 21,197 $ 23,102
Cost of sales (2,873) (3,079) (8,786) (9,092)
Gross profit $ 4,000 $ 4,584 $ 12,411 $ 14,010
Gross profit margin 58.2 % 59.8 % 58.6 % 60.6 %
Cost of sales decreased year-over-year during both the three and nine-month periods ended September 29, 2023 as
compared to the comparable periods in 2022, primarily due to lower year-over-year sales volumes, partially offset in the
nine-month period by costs associated with restructuring and continuing productivity initiatives and $87 million of charges
incurred in the second quarter of 2023, primarily related to excess inventory in the Biotechnology segment, due to reduced
demand. In the first quarter of 2022, the Company incurred inventory charges related to the reduction of business
activities in Russia.
Year-over-year gross profit margins decreased during both the three and nine-month periods ended September 29, 2023
as compared to the comparable periods in 2022 due primarily to lower core sales and the impact of product mix in both
periods. Year-over-year gross profit margin for the nine-month period was unfavorably impacted by costs associated with
restructuring and continuing productivity initiatives and the $87 million of charges in the second quarter of 2023 referenced
in the preceding paragraph, net of an inventory charge taken during the first quarter of 2022 related to reduction of
business activities in Russia.
OPERATING EXPENSES
Three-Month Period Ended Nine-Month Period Ended
($ in millions) September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Sales $ 6,873 $ 7,663 $ 21,197 $ 23,102
Selling, general and administrative (“SG&A”)
expenses 2,145 2,149 6,486 6,326
Research and development (“R&D”)
expenses 417 420 1,264 1,292
SG&A as a % of sales 31.2 % 28.0 % 30.6 % 27.4 %
R&D as a % of sales 6.1 % 5.5 % 6.0 % 5.6 %
SG&A expenses as a percentage of sales increased for both the three and nine-month periods ended September 29,
2023 as compared to the comparable periods in 2022, driven by the impact of decreased leverage of the Company’s
general and administrative cost base, including amortization expense, resulting from lower 2023 sales. Costs incurred
related to preparation for the separation of the Company’s Environmental & Applied Solutions business of $36 million and
$101 million for the three and nine-month periods ended September 29, 2023, respectively, and impairment charges
totaling $6 million and $40 million in the three and nine-month periods ended September 29, 2023, respectively, also
negatively impacted SG&A expenses as a percentage of sales. These impairment charges consisted of $6 million in the
three-month period in the Environmental & Applied Solutions segment related to a trade name, $28 million in the nine-
month period in the Biotechnology segment related to technology and other assets, and $12 million in the nine-month
period in the Environmental & Applied Solutions segment related to customer relationships and a trade name, net of a $9
million second quarter 2022 impairment charge related to technology and customer relationships in the Environmental &
Applied Solutions segment. Increased labor costs also contributed to the year-over-year increase in SG&A expenses for
the three and nine-month periods. Costs associated with restructuring and continuing productivity initiatives decreased
year-over-year for the three-month period and increased year-over year for the nine-month period. For the nine-month
period, these increases were partially offset by the impact of a charge related to impairments of certain accounts
receivable and accrual of contractual obligations incurred in Russia during the first quarter of 2022.
Table of Contents
36

-- 39 of 49 --

R&D expenses (consisting principally of internal and contract engineering personnel costs) as a percentage of sales
increased during both the three and nine-month periods ended September 29, 2023 as compared to the comparable
periods of 2022, primarily due to the year-over-year sales decline and to a lesser extent the timing of new product
development initiatives.
OTHER INCOME (EXPENSE), NET
For a description of the Company’s other income (expense), net during the three and nine-month periods ended
September 29, 2023 and September 30, 2022, refer to Note 8 to the accompanying Consolidated Condensed Financial
Statements.
INTEREST COSTS AND FINANCING
For a discussion of the Company’s outstanding indebtedness, refer to Note 11 to the accompanying Consolidated
Condensed Financial Statements.
Interest expense of $73 million and $208 million for the three and nine-month periods ended September 29, 2023,
respectively, was $31 million higher and $61 million higher than the comparable periods of 2022, due primarily to higher
balances and higher average interest rates on the Company’s outstanding euro-denominated commercial paper
borrowings in the three and nine-month periods in 2023 versus the comparable periods of 2022.
Interest income of $79 million and $186 million for the three and nine-month periods ended September 29, 2023,
respectively, was $70 million higher and $174 million higher than the comparable periods of 2022, due primarily to higher
average interest rates and higher average cash balances in 2023 compared to 2022.
INCOME TAXES
The following table summarizes the Company’s effective tax rate:
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Effective tax rate 19.2 % 18.6 % 19.7 % 18.4 %
The Company operates globally, including in certain jurisdictions with lower tax rates than the U.S. federal statutory rate.
Therefore, the impact of operating in such jurisdictions contributes to a lower effective tax rate compared to the U.S.
federal statutory tax rate.
The effective tax rate for the three-month period ended September 29, 2023 differs from the U.S. federal statutory rate of
21.0% due to the geographic mix of earnings described above. Discrete tax benefits from excess tax benefits from stock-
based compensation were offset by charges related to tax costs related to the separation of the Environmental & Applied
Solutions business and changes in estimates associated with prior period uncertain tax positions.
The effective tax rate for the nine-month period ended September 29, 2023 differs from the U.S. federal statutory rate of
21.0% principally due to the geographic mix of earnings described above, partially offset by net discrete tax charges of
$13 million. Net discrete tax charges related primarily to tax costs related to the separation of the Environmental &
Applied Solutions business, tax costs related to legal and operational actions taken to realign certain businesses and
changes in estimates associated with prior period uncertain tax positions, partially offset by excess tax benefits from
stock-based compensation and interest on prior year tax refunds. The net discrete charges increased the effective tax
rate by 0.3% for the nine-month period ended September 29, 2023.
The effective tax rate for the three-month period ended September 30, 2022 differs from the U.S. federal statutory rate of
21.0% principally due to the geographic mix of earnings described above and net discrete benefits of $3 million related
primarily to excess tax benefits from stock-based compensation, partially offset by changes in estimates associated with
prior period uncertain tax positions. The net discrete benefits reduced the effective tax rate by 0.2% for the three-month
period ended September 30, 2022.
The effective tax rate for the nine-month period ended September 30, 2022 differs from the U.S. federal statutory rate of
21.0% principally due the geographic mix of earnings described above and net discrete benefits of $52 million related
primarily to excess tax benefits from stock-based compensation and changes in estimates associated with prior period
uncertain tax positions. The net discrete benefits reduced the effective tax rate by 0.9% for the nine-month period ended
September 30, 2022.
The Company (including its subsidiaries) conducts business globally, and files numerous consolidated and separate
income tax returns in federal, state and foreign jurisdictions. In addition to the Company’s significant presence in the U.S.,
the Company also has a significant presence in China, Denmark, Germany, Singapore, Sweden, Switzerland and the
Table of Contents
37

-- 40 of 49 --

United Kingdom (“UK”). Excluding these jurisdictions, the Company believes that a change in the statutory tax rate of any
individual foreign country would not have a material impact on the Company’s financial statements given the geographical
dispersion of the Company’s taxable income.
The Company and its subsidiaries are routinely examined by various domestic and international taxing authorities. The
U.S. Internal Revenue Service (“IRS”) has completed the examinations of substantially all of the Company’s federal
income tax returns through 2015 and is currently examining certain of the Company’s federal income tax returns for 2016
through 2021. In addition, the Company has subsidiaries in Belgium, Canada, China, Denmark, France, Germany, India,
Italy, Japan, Korea, Switzerland, the UK and various other countries, states and provinces that are currently under audit
for years ranging from 2004 through 2022.
In the fourth quarter of 2022, the IRS proposed significant adjustments to the Company’s taxable income for the years
2016 through 2018 with respect to the deferral of tax on certain premium income related to the Company’s self-insurance
programs. For income tax purposes, the recognition of premium income has been deferred in accordance with U.S. tax
laws related to insurance. The IRS challenged the deferral of premium income for certain types of the Company’s self-
insurance policies. The proposed adjustments would have increased the Company’s taxable income over the 2016
through 2018 periods by approximately $2.5 billion. In the first quarter of 2023, the Company settled these proposed
adjustments with the IRS, although the audit is still open with respect to other matters for the 2016 through 2018 period.
The impact of the settlement with respect to the Company’s self-insurance policies was not material to the Company’s
financial statements, including cash flows and the effective tax rate. As the settlement with the IRS was specific to the
audit period, the settlement does not preclude the IRS from proposing similar adjustments to the Company’s self-
insurance programs with respect to periods subsequent to 2018. Management believes the positions the Company has
taken in its U.S. tax returns are in accordance with the relevant tax laws.
As a result of the completion of the Separation in the fourth quarter of 2023, the Company expects its effective tax rate for
the remainder of 2023 to be approximately 18.5% based on its projected mix of earnings. The Company’s effective tax
rate could vary as a result of many factors, including but not limited to the following:
• The expected rate for the remainder of 2023 includes the anticipated discrete income tax benefits from excess tax
deductions related to the Company’s stock compensation programs, which are reflected as a reduction in tax
expense, though the actual benefits (if any) will depend on the Company’s stock price and stock option exercise
patterns.
• The actual mix of earnings by jurisdiction could fluctuate from the Company’s projection, including as a result of
the separation of the Environmental & Applied Solutions business.
• The tax effects of other discrete items, including accruals related to tax contingencies, the resolution of worldwide
tax matters, tax audit settlements, statute of limitations expirations and changes in tax regulations.
• Any future changes in tax law or the implementation of increases in tax rates, the impact of future regulations and
any related additional tax planning efforts to address these changes.
As a result of the uncertainty in predicting these items, it is reasonably possible that the actual effective tax rate used for
financial reporting purposes will change in future periods.
Refer to Note 7 to the Consolidated Condensed Financial Statements for discussion regarding the Company’s significant
tax matters.
COMPREHENSIVE INCOME
In 2023, comprehensive income increased $283 million and $448 million for the three and nine-month periods ended
September 29, 2023, respectively, as compared to the comparable periods of 2022. For the three-month period, the
increase in comprehensive income was primarily driven by decreased losses from foreign currency translation
adjustments, partially offset by lower net earnings. For the nine-month period, the increase in comprehensive income was
primarily driven by lower losses from foreign currency translation adjustments, partially offset by lower net earnings and
increased losses from cash flow hedge adjustments. The Company recorded foreign currency translation losses of $303
million for the three-month period ended September 29, 2023 compared to losses of approximately $1.0 billion for the
three-month period ended September 30, 2022. The Company recorded foreign currency translation losses of $982
million and approximately $2.8 billion for the nine-month periods ended September 29, 2023 and September 30, 2022,
respectively. The foreign currency translation losses were primarily driven by the change in the exchange rates between
the U.S. dollar and the Swedish krona in both periods, as well as the euro during the three-month period and the Chinese
renminbi in the nine-month period. Foreign currency translation adjustments reflect the gain or loss resulting from the
impact of the change in currency exchange rates on the Company’s foreign operations as they are translated to the
Company’s reporting currency, the U.S. dollar. The Company recorded losses of $81 million and $106 million from cash
Table of Contents
38

-- 41 of 49 --

flow hedge adjustments related to the Company’s cross-currency swap derivative contracts for the three and nine-month
periods ended September 29, 2023, respectively, as compared to losses of $77 million and $31 million for the comparable
periods of 2022.
LIQUIDITY AND CAPITAL RESOURCES
Management assesses the Company’s liquidity in terms of its ability to generate cash to fund its operating, investing and
financing activities. The Company continues to generate substantial cash from operating activities and believes that its
operating cash flow, cash on hand and other sources of liquidity will be sufficient to allow it to continue investing in existing
businesses (including capital expenditures), consummating strategic acquisitions and investments, paying interest and
servicing debt, paying dividends, funding restructuring activities, repurchasing common stock and managing its capital
structure on a short-term and long-term basis.
The Company has relied primarily on borrowings under its commercial paper program to address liquidity requirements
that exceed the capacity provided by its operating cash flows and cash on hand, while also accessing the capital markets
from time to time including to secure financing for more significant acquisitions. Subject to any limitations that may result
from market disruptions, the Company anticipates following the same approach in the future.
Overview of Cash Flows and Liquidity
Following is an overview of the Company’s cash flows and liquidity ($ in millions):
Nine-Month Period Ended
($ in millions) September 29, 2023 September 30, 2022
Total operating cash provided by operations $ 5,545 $ 5,978
Cash paid for acquisitions $ — $ (304)
Payments for additions to property, plant and equipment (981) (823)
Proceeds from sales of property, plant and equipment 8 9
Payments for purchases of investments (152) (354)
Proceeds from sales of investments 33 18
All other investing activities 28 36
Total cash used in investing activities $ (1,064) $ (1,418)
Proceeds from the issuance of common stock in connection with stock-based
compensation, net $ 51 $ 15
Payment of dividends (621) (615)
Net proceeds from borrowings (maturities longer than 90 days) 2,605 —
Net repayments of borrowings (maturities of 90 days or less) (9) (719)
Net repayments of borrowings (maturities longer than 90 days) — (265)
All other financing activities (53) (80)
Total cash provided by (used in) financing activities $ 1,973 $ (1,664)
• Operating cash flows decreased $433 million, or 7%, during the nine-month period ended September 29, 2023 as
compared to the comparable period of 2022, due to lower net earnings (after excluding in both periods charges
for depreciation, amortization, stock compensation and unrealized investment gains/losses) in the 2023 period
compared to the 2022 period and lower cash used in aggregate for accounts receivables, inventories, trade
accounts payable and prepaid and accrued expenses, including deferred taxes, in 2023 compared to the prior
year.
• In September 2023, Veralto received approximately $2.6 billion of cash proceeds from the issuance of debt (refer
to Note 11 of the accompanying Consolidated Condensed Financial Statements), of which approximately
$2.6 billion was distributed to the Company as partial consideration for the contribution to Veralto of the
businesses comprising the Company’s former Environmental & Applied Solutions segment. The Company
intends to use a portion of the cash distribution proceeds it received from Veralto to meet upcoming commercial
paper and bond maturities and to use the balance of the proceeds to partially fund certain of the Company’s
regular, quarterly cash dividends to shareholders.
Table of Contents
39

-- 42 of 49 --

• Net cash used in investing activities in the 2023 period consisted primarily of capital expenditures and
investments and decreased year-over-year largely as a result of lower cash paid for acquisitions and investments
in the 2023 period compared to 2022.
• As of September 29, 2023, the Company held approximately $12.3 billion of cash and cash equivalents.
Operating Activities
Cash flows from operating activities can fluctuate significantly from period-to-period as working capital needs and the
timing of payments for income taxes, restructuring activities and productivity improvement initiatives, pension funding and
other items impact reported cash flows.
Operating cash flows were approximately $5.5 billion for the first nine months of 2023, a decrease of $433 million, or 7%,
as compared to the comparable period of 2022. The year-over-year change in operating cash flows from 2022 to 2023
was primarily attributable to the following factors:
• 2023 operating cash flows reflected a decrease of approximately $1.3 billion in net earnings for the first nine
months of 2023 as compared to the comparable period in 2022.
• Net earnings for the first nine months of 2023 also includes $102 million lower noncash charges for depreciation,
intangible asset amortization, stock compensation expense and unrealized investment gains/losses as compared
to the comparable period of 2022. Amortization expense primarily relates to the amortization of intangible assets.
Depreciation expense relates to the Company’s manufacturing and operating facilities as well as instrumentation
leased to customers under operating-type lease (“OTL”) arrangements. Depreciation, amortization and stock
compensation are noncash expenses that decrease earnings without a corresponding impact to operating cash
flows. Unrealized investment gains/losses impact net earnings without immediately impacting cash flows as the
cash flow impact from investments occurs when the invested capital is returned to the Company.
• The aggregate of trade accounts receivable, inventories and trade accounts payable provided $285 million in
operating cash flows during the first nine months of 2023, compared to approximately $1.0 billion of operating
cash flows used in the comparable period of 2022. The amount of cash flow generated from or used by the
aggregate of trade accounts receivable, inventories and trade accounts payable depends upon how effectively
the Company manages the cash conversion cycle, which effectively represents the number of days that elapse
from the day it pays for the purchase of raw materials and components to the collection of cash from its
customers and can be significantly impacted by the timing of collections and payments in a period.
• The aggregate of prepaid expenses and other assets, deferred income taxes and accrued expenses and other
liabilities used $436 million of operating cash flows during the first nine months of 2023, compared to $69 million
of operating cash flows used in the comparable period of 2022. The timing of cash payments for various
employee-related liabilities, higher income tax payments, realized investment returns, customer funding and
changes in accrued expenses drove the majority of this change.
Investing Activities
Cash flows relating to investing activities consist primarily of cash used for acquisitions and capital expenditures, including
instruments leased to customers, cash used for investments and cash proceeds from divestitures of businesses or assets.
Net cash used in investing activities decreased $354 million in the nine-month period ended September 29, 2023
compared to the comparable period of 2022, primarily as a result of a decrease in cash used for the purchase of
investments. In the first nine months of 2023 and 2022, the Company invested $152 million and $354 million,
respectively, in non-marketable equity securities and partnerships.
Though the relative significance of particular categories of capital investment can change from period to period, capital
expenditures are typically made for increasing manufacturing capacity, replacing equipment, the manufacture of
instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers,
supporting new product development and improving IT systems. Capital expenditures increased $158 million on a year-
over-year basis for the nine-month period ended September 29, 2023 compared to the comparable period in 2022. For
the full year 2023, the Company forecasts capital spending to be approximately $1.5 billion (excluding capital spending
during 2023 with respect to the businesses contributed to Veralto in the Separation), driven primarily by continued
expenditures to support customer demand.
Table of Contents
40

-- 43 of 49 --

Financing Activities and Indebtedness
Cash flows relating to financing activities consist of cash flows associated with the issuance and repayments of
commercial paper, issuance and repayment of long-term debt, borrowings under committed credit facilities, issuance and
repurchases of common stock, issuance of preferred stock and payments of cash dividends to shareholders. Financing
activities provided cash of approximately $2.0 billion during the nine-month period ended September 29, 2023 compared
to approximately $1.7 billion of cash used in the comparable period of 2022. The year-over-year increase in cash
provided by financing activities was due primarily to approximately $2.6 billion of cash proceeds received from Veralto’s
debt issuance in September 2023 (which Veralto subsequently distributed to the Company prior to the Separation),
partially offset by lower repayments of borrowings in 2023.
For a description of the Company’s outstanding debt as of September 29, 2023 and the Company’s commercial paper
programs and credit facility, refer to Note 11 to the accompanying Consolidated Condensed Financial Statements. As of
September 29, 2023, the Company was in compliance with all of its respective debt covenants.
As discussed in Note 15 in the accompanying Consolidated Condensed Financial Statements all outstanding shares of
the Company’s 4.75% MCPS Series A and 5.00% MCPS Series B were converted to common shares on April 15, 2022
and April 17, 2023, respectively. The Company’s 4.75% MCPS Series A converted to common shares at a rate of 6.6632
common shares per share of preferred stock. The Company’s 5.00% MCPS Series B converted to common shares at a
rate of 5.0175 common shares per share of preferred stock.
Stock Repurchase Program
For information regarding the Company’s stock repurchase program, refer to Part II—Item 2, “Unregistered Sales of
Equity Securities and Use of Proceeds”.
Dividends
Aggregate cash payments for dividends on Company common stock during the nine-month period ended September 29,
2023 were $578 million and aggregate cash payments for dividends on the Company’s MCPS during the nine-month
period ended September 29, 2023 were $43 million. The increase in dividend payments on the Company’s common stock
over the comparable period of 2022 primarily relates to the increase in the quarterly dividend rate for common stock
beginning with respect to the dividend paid in the second quarter of 2023. The decrease in MCPS dividend payments
compared to the comparable period of 2022 primarily relates to the conversion of all outstanding shares of the Company’s
4.75% MCPS Series A and the 5.00% MCPS Series B to common shares on April 15, 2022 and April 17, 2023,
respectively.
In the third quarter of 2023, the Company declared a regular quarterly dividend of $0.27 per share of Company common
stock payable on October 27, 2023 to holders of record as of October 12, 2023.
Cash and Cash Requirements
As of September 29, 2023, the Company held approximately $12.3 billion of cash and cash equivalents that were held on
deposit with financial institutions or invested in highly liquid investment-grade debt instruments with a maturity of 90 days
or less. Of the cash and cash equivalents, approximately $6.8 billion was held within the United States and approximately
$5.5 billion was held outside of the United States. The Company will continue to have cash requirements to support
general corporate purposes, which may include working capital needs, capital expenditures, acquisitions (including the
Company’s pending acquisition of Abcam) and investments, paying interest and servicing debt, paying taxes and any
related interest or penalties, funding its restructuring activities and pension plans as required, paying dividends to
shareholders, repurchasing shares of the Company’s common stock and supporting other business needs.
The Company generally intends to use available cash and internally generated funds to meet these cash requirements,
but in the event that additional liquidity is required, the Company may also borrow under its commercial paper programs (if
available) or borrow under the Company’s Credit Facility, enter into new credit facilities and either borrow directly
thereunder or use such credit facilities to backstop additional borrowing capacity under its commercial paper programs (if
available) and/or access the capital markets (if available). The Company also may from time to time seek to access the
capital markets to take advantage of favorable interest rate environments or other market conditions. With respect to the
commercial paper and other notes scheduled to mature during the remainder of 2023, the Company expects to repay the
principal amounts when due using available cash, proceeds from new issuances of commercial paper (if available),
drawing on its Credit Facility and/or proceeds from other debt issuances. With respect to the pending acquisition of
Abcam, Danaher expects to fund the acquisition using cash on hand and proceeds from the issuance of commercial
paper.
Table of Contents
41

-- 44 of 49 --

While repatriation of some cash held outside the United States may be restricted by local laws, most of the Company’s
foreign cash could be repatriated to the United States. Following enactment of the Tax Cuts and Jobs Act and the
associated Transition Tax, in general, repatriation of cash to the United States can be completed with no incremental U.S.
tax; however, repatriation of cash could subject the Company to non-U.S. taxes on distributions. The cash that the
Company’s non-U.S. subsidiaries hold for indefinite reinvestment is generally used to finance foreign operations and
investments, including acquisitions. The income taxes, if any, applicable to such earnings including basis differences in
our foreign subsidiaries are not readily determinable. As of September 29, 2023, management believes that it has
sufficient sources of liquidity to satisfy its cash needs, including its cash needs in the United States.
During 2023, the Company’s cash contribution requirements for its U.S. and non-U.S. defined benefit pension plans are
forecasted to be approximately $10 million and $39 million, respectively. The ultimate amounts to be contributed depend
upon, among other things, legal requirements, underlying asset returns, the plan’s funded status, the anticipated tax
deductibility of the contribution, local practices, market conditions, interest rates and other factors.
CRITICAL ACCOUNTING ESTIMATES
There have been no material changes to the Company’s critical accounting estimates as described in the 2022 Annual
Report.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Quantitative and qualitative disclosures about market risk appear in “Management’s Discussion and Analysis of Financial
Condition and Results of Operations—Financial Instruments and Risk Management,” in the Company’s 2022 Annual
Report. There were no material changes during the quarter ended September 29, 2023 to this information as reported in
the Company’s 2022 Annual Report.
ITEM 4. CONTROLS AND PROCEDURES
The Company’s management, with the participation of the Company’s President and Chief Executive Officer, and
Executive Vice President and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure
controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of
1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, the
Company’s President and Chief Executive Officer, and Executive Vice President and Chief Financial Officer, have
concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective.
Except as set forth below, there have been no changes in the Company’s internal control over financial reporting (as such
term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the Company’s most recent
completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal
control over financial reporting.
In January 2023, the Company began integrating various business processes within its Biotechnology businesses,
including the transition of certain activities to one existing common enterprise resource planning system and to common
applications used for various financial reporting and operational purposes. In connection with this integration and related
business process changes, the Company replaced certain internal controls with new or modified controls. The integration
is being executed in phases throughout 2023 and is intended to support customer requirements and accommodate future
business demands.
Table of Contents
42

-- 45 of 49 --

PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
For additional information regarding legal proceedings, refer to the section titled “Legal Proceedings” in the MD&A section
of the Company’s 2022 Annual Report.
ITEM 1A. RISK FACTORS
Information regarding risk factors can be found in “Management’s Discussion and Analysis of Financial Condition and
Results of Operations—Information Related to Forward-Looking Statements,” in Part I—Item 2 of this Form 10-Q and in
Part I—Item 1A of Danaher’s 2022 Annual Report on Form 10-K.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Neither the Company nor any “affiliated purchaser” repurchased any shares of Company common stock during the three-
month period ended September 29, 2023. On July 16, 2013, the Company’s Board of Directors approved a repurchase
program (the “Repurchase Program”) authorizing the repurchase of up to 20 million shares of the Company’s common
stock from time to time on the open market or in privately negotiated transactions. As of September 29, 2023,
approximately 20 million shares remained available for repurchase pursuant to the Repurchase Program. There is no
expiration date for the Repurchase Program, and the timing and amount of any future shares repurchased under the
program will be determined by members of the Company’s management based on its evaluation of market conditions and
other factors. The Repurchase Program may be suspended or discontinued at any time. Any repurchased shares will be
available for use in connection with the Company’s equity compensation plans (or any successor plans) and for other
corporate purposes. The Company expects to fund any future stock repurchases using the Company’s available cash
balances or proceeds from the issuance of debt.
ITEM 5. OTHER INFORMATION
Director and Officer Trading Arrangements
None of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule
10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this
report.
Table of Contents
43

-- 46 of 49 --

ITEM 6. EXHIBITS
(a) Exhibits:
2.1 Separation and Distribution Agreement, dated as of September 29, 2023, by and between Danaher
Corporation and Veralto Corporation (incorporated by reference to Exhibit 2.1 to Danaher Corporation’s
Current Report on Form 8-K filed on October 2, 2023)
3.1 Restated Certificate of Incorporation of Danaher Corporation (incorporated by reference from Exhibit 3.1 to
Danaher Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 29, 2012)
3.2 Certificate of Elimination relating to Preferred Stock, filed with the Secretary of State of the State of Delaware
on May 09, 2023 (incorporated by reference from Exhibit 3.1 to Danaher Corporation’s Current Report on
Form 8-K filed May 11, 2023)
3.3 Amended and Restated By-laws of Danaher Corporation (incorporated by reference from Exhibit 3.1 to
Danaher Corporation’s Current Report on Form 8-K filed December 7, 2022)
10.1 Employee Matters Agreement, dated as of September 29, 2023, by and between Danaher Corporation and
Veralto Corporation (incorporated by reference to Exhibit 10.1 to Danaher Corporation’s Current Report on
Form 8-K filed on October 2, 2023)
10.2 Tax Matters Agreement, dated as of September 29, 2023, by and between Danaher Corporation and Veralto
Corporation (incorporated by reference to Exhibit 10.2 to Danaher Corporation’s Current Report on Form 8-K
filed on October 2, 2023)
10.3 Transition Services Agreement, dated as of September 29, 2023, by and between Danaher Corporation and
Veralto Corporation (incorporated by reference to Exhibit 10.3 to Danaher Corporation’s Current Report on
Form 8-K filed on October 2, 2023)
10.4 Intellectual Property Matters Agreement, dated as of September 29, 2023, by and between Danaher
Corporation and Veralto Corporation (incorporated by reference to Exhibit 10.4 to Danaher Corporation’s
Current Report on Form 8-K filed on October 2, 2023)
10.5 DBS License Agreement, dated as of September 29, 2023, by and between Danaher Corporation and Veralto
Corporation (incorporated by reference to Exhibit 10.5 to Danaher Corporation’s Current Report on Form 8-K
filed on October 2, 2023)
10.6 Third Amended and Restated Credit Agreement, dated as of August 11, 2023, among Danaher Corporation,
certain of its subsidiaries party thereto, Bank of America, N.A., as Administrative Agent, and the lenders
referred to therein (incorporated by reference to Exhibit 10.1 to Danaher Corporation’s Current Report on
Form 8-K filed on August 15, 2023)
10.7 Credit Agreement, dated as of August 31, 2023, among Veralto Corporation, certain of its subsidiaries party
thereto, Bank of America, N.A., as Administrative Agent, and the lenders referred to therein (incorporated by
reference to Exhibit 10.1 to Danaher Corporation’s Current Report on Form 8-K filed on August 31, 2023)
10.8 Indenture, dated as of September 18, 2023, between Veralto Corporation, as issuer, and Deutsche Bank
Trust Company Americas, a New York banking corporation, as trustee (incorporated by reference to Exhibit
4.1 to Danaher Corporation’s Current Report on Form 8-K filed on September 19, 2023)
10.9 Guarantee Agreement, dated as of September 18, 2023, made by Danaher Corporation (incorporated by
reference to Exhibit 4.2 to Danaher Corporation’s Current Report on Form 8-K filed on September 19, 2023)
10.10 Indenture, dated as of September 19, 2023, between Veralto Corporation, as issuer, and Deutsche Bank
Trust Company Americas, a New York banking corporation, as trustee (incorporated by reference to Exhibit
4.3 to Danaher Corporation’s Current Report on Form 8-K filed on September 19, 2023)
10.11 Guarantee Agreement, dated as of September 19, 2023, made by Danaher Corporation (incorporated by
reference to Exhibit 4.4 to Danaher Corporation’s Current Report on Form 8-K filed on September 19, 2023)
10.12 Amendment to Danaher Deferred Compensation Plan
10.13 Amendment to Danaher Executive Deferred Incentive Program
10.14 Amendment to Danaher Excess Contribution Program
10.15 Management Agreement dated September 29, 2023 by and between FJ900, Inc. and Joust Capital II, LLC (1)
10.16 Interchange Agreement dated September 29, 2023 by and between Danaher Corporation and Joust Capital
II, LLC
22.1 Subsidiary guarantors and issuers of guaranteed securities and affiliates whose securities collateralize
securities of the Registrant
Table of Contents
44

-- 47 of 49 --

31.1 Certification of Chief Executive Officer Pursuant to Item 601(b)(31) of Regulation S-K, As Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
31.2 Certification of Chief Financial Officer Pursuant to Item 601(b)(31) of Regulation S-K, As Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
32.1 Certification of Chief Executive Officer, Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section
906 of the Sarbanes-Oxley Act of 2002
32.2 Certification of Chief Financial Officer, Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section
906 of the Sarbanes-Oxley Act of 2002
101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File
because its XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
(1) In accordance with Instruction 2 to Item 601(a)(4) of Regulation S-K, FJ900, Inc. (a subsidiary of Danaher) has entered into a
management agreement with Stonehavens Global LLC that is substantially identical in all material respects to the form of
agreement referenced as Exhibit 10.15, except as to name of the counterparty.
Table of Contents
45

-- 48 of 49 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly authorized.
DANAHER CORPORATION
Date: October 23, 2023 By: /s/ Matthew R. McGrew
Matthew R. McGrew
Executive Vice President and Chief Financial Officer
Date: October 23, 2023 By: /s/ Christopher M. Bouda
Christopher M. Bouda
Vice President and Chief Accounting Officer
Table of Contents
46

-- 49 of 49 --